EP3902799B1 - Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method - Google Patents
Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method Download PDFInfo
- Publication number
- EP3902799B1 EP3902799B1 EP20700830.1A EP20700830A EP3902799B1 EP 3902799 B1 EP3902799 B1 EP 3902799B1 EP 20700830 A EP20700830 A EP 20700830A EP 3902799 B1 EP3902799 B1 EP 3902799B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- complex
- hexaacid
- gadolinium
- rrr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052688 Gadolinium Inorganic materials 0.000 title claims description 104
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 title claims description 104
- 239000003446 ligand Substances 0.000 title description 7
- 238000001308 synthesis method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 63
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 claims description 43
- 230000008569 process Effects 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 36
- 239000007864 aqueous solution Substances 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000002425 crystallisation Methods 0.000 claims description 24
- 230000008025 crystallization Effects 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 238000006317 isomerization reaction Methods 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 17
- 150000005691 triesters Chemical class 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000010668 complexation reaction Methods 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 238000001953 recrystallisation Methods 0.000 claims description 10
- 238000007098 aminolysis reaction Methods 0.000 claims description 9
- 239000012429 reaction media Substances 0.000 claims description 9
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000010899 nucleation Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- -1 methyl triester Chemical class 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- WZAIBHOPSSMDTE-UHFFFAOYSA-N dibutyl 2-bromopentanedioate Chemical compound CCCCOC(=O)CCC(Br)C(=O)OCCCC WZAIBHOPSSMDTE-UHFFFAOYSA-N 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000005804 alkylation reaction Methods 0.000 claims description 4
- 230000029936 alkylation Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 238000005292 vacuum distillation Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 18
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 16
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 150000002148 esters Chemical group 0.000 description 14
- 238000005755 formation reaction Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 150000001408 amides Chemical group 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 150000002678 macrocyclic compounds Chemical class 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229910052747 lanthanoid Inorganic materials 0.000 description 7
- 150000002602 lanthanoids Chemical class 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 150000008065 acid anhydrides Chemical class 0.000 description 6
- 150000001263 acyl chlorides Chemical class 0.000 description 6
- 238000007112 amidation reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229940075613 gadolinium oxide Drugs 0.000 description 5
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
- 238000000825 ultraviolet detection Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 4
- 150000000921 Gadolinium Chemical class 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 101001042415 Cratylia mollis Mannose/glucose-specific lectin Cramoll Proteins 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 241001080024 Telles Species 0.000 description 3
- 241000364019 Theisoa Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000004819 silanols Chemical class 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 description 2
- NFPWGFSRWDHFFT-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid gadolinium Chemical compound [Gd].CNC(=O)CN(CCN(CCN(CC(O)=O)CC(=O)NC)CC(O)=O)CC(O)=O NFPWGFSRWDHFFT-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 125000004018 acid anhydride group Chemical group 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- OXJSWZSWGJACGU-UHFFFAOYSA-N diethyl 2-bromopentanedioate Chemical compound CCOC(=O)CCC(Br)C(=O)OCC OXJSWZSWGJACGU-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960003411 gadobutrol Drugs 0.000 description 2
- 229960005063 gadodiamide Drugs 0.000 description 2
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 2
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 2
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000004457 water analysis Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 description 1
- 125000006530 (C4-C6) alkyl group Chemical group 0.000 description 1
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NGJUYARYEXGDNN-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-3-ethylurea Chemical compound CCNC(=O)NCCCN(C)C NGJUYARYEXGDNN-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VABLTLMVVFQNBE-UHFFFAOYSA-N 4-bromo-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)C(Br)CCC(O)=O VABLTLMVVFQNBE-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- JZZJYKCGQJWUDV-UHFFFAOYSA-N C[Gd](C)C Chemical compound C[Gd](C)C JZZJYKCGQJWUDV-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- ILCLBMDYDXDUJO-UHFFFAOYSA-K gadolinium(3+);trihydroxide Chemical compound [OH-].[OH-].[OH-].[Gd+3] ILCLBMDYDXDUJO-UHFFFAOYSA-K 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 229940005649 gadopentetate Drugs 0.000 description 1
- 229940016115 gadoterate meglumine Drugs 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 description 1
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic System without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a new process for the synthesis of a complex of gadolinium and a chelating ligand derived from PCTA, which makes it possible to preferentially obtain the stereoisomers of said complex which have physicochemical properties which are particularly advantageous for applications as a contrast agent in the field of medical imaging, in particular for Magnetic Resonance Imaging.
- contrast agents based on lanthanide chelates in particular gadolinium (Gd)
- gadolinium Gd
- GBCA Gadolinium-based Contrast Agent, contrast products based on gadolinium
- chelates such as gadoterate meglumine based on DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N′′′-tetraacetic acid), gadobutrol based on DO3A-butrol, gadoteridol based on HPDO3A, as well as linear chelates, in particular based on DTPA (diethylenetriaminepentaacetic acid) or DTPA-BMA (ligand of gadodiamide).
- DOTA diethylenetriaminepentaacetic acid
- DTPA-BMA ligand of gadodiamide
- the chelates (or complexes) of lanthanide - and in particular of gadolinium - are in a situation of chemical equilibrium (characterized by its thermodynamic constant K therm ), which can lead to an undesired release of said lanthanide (see equation 1 below):
- NSF Neurogenic Systemic Fibrosis, systemic nephrogenic fibrosis or fibrogenic dermopathy
- a strategy for limiting the risk of release of lanthanide in the organism thus consists in opting for complexes which are distinguished by the highest possible thermodynamic and/or kinetic stability. Indeed, the more the complex is stable, the more the quantity of lanthanide released over time will be limited.
- the complexes of chelating ligands derived from PCTA comprising a structure of the pyclene type described in the document EP 1 931 673 , while having good kinetic stability, have, in general, a lower thermodynamic constant than that of the complexes of the other cyclene-derived macrocycles.
- the complex of formula (II) corresponds to several stereoisomers, in particular due to the presence of the three asymmetric carbon atoms located in position ⁇ on the side chains of the complex, with respect to the nitrogen atoms of the macrocycle on which said side chains are grafted. These three asymmetric carbons are marked with an asterisk (*) in formula (II) shown above.
- the aminopropanediol groups of the side chains of the complex of formula (II) also contain an asymmetric carbon.
- the complex of formula (II) comprises a total of 6 asymmetric carbons, and therefore exists in the form of 64 configurational stereoisomers.
- the only source of stereoisomerism considered for a given side chain will be, for the sake of simplification, that corresponding to the asymmetric carbon bearing the carboxylate group, marked with an asterisk (*) in the formula (II ) shown above.
- each of these 3 asymmetric carbons can be of absolute configuration R or S
- the complex of formula (II) exists in the form of 8 families of stereoisomers, called hereinafter II-RRR, II-SSS, II- RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS. More precisely, according to the usual nomenclature in stereochemistry, the complex of formula (II) exists in the form of 8 families of diastereoisomers.
- HPLC high performance liquid chromatography
- UHCP ultra high performance liquid phase chromatography
- iso1, iso2, iso3 and iso4 4 masses or groups of isomers of the complex of formula (II) obtained according to the method of the prior art, corresponding to 4 different elution peaks characterized by their retention time on the chromatogram, which will be called iso1, iso2, iso3 and iso4 in the following description.
- iso4 which includes a mixture of the II-RRR and II-SSS isomers with the formulas (II-RRR ) and (II-SSS) represented below, proves to be the most advantageous as a contrast agent for medical imaging.
- iso4 is distinguished, surprisingly, by a much greater thermodynamic stability than that of the mixture of diastereoisomers in the form of which the complex of formula (II) is obtained by implementing the process described in the document EP 1 931 673 .
- gadobutrol or gadoterate, macrocyclic gadolinium complexes respectively show a kinetic inertia of 18 hours and 4 days under the same conditions, while linear gadolinium complexes such as gadodiamide or gadopentetate dissociate instantaneously.
- iso4 is more stable from a chemical point of view than iso3 in particular.
- the amide functions of the complex of formula (II) are indeed capable of being hydrolyzed.
- the hydrolysis reaction of an amide function (equation 3) results in the formation of a dicoupled impurity, which is accompanied by the release of 3-amino-1,2-propanediol.
- the inventors have studied the kinetics of the hydrolysis reaction of the complex of formula (II) in aqueous solution at pH 13, and observed that the amide functions of iso4 are more stable with respect to hydrolysis than those of iso3.
- the inventors have succeeded in developing a new process for preparing the complex of formula (II) making it possible to preferentially obtain the II-RRR and II-SSS diastereoisomers of said complex, which have particularly advantageous physicochemical properties.
- the process according to the invention comprises an isomeric enrichment step, by conversion of the least stable stereoisomers to the most stable stereoisomers, which, surprisingly, while being carried out on the intermediate hexaacid complex and not on the final complex , makes it possible to obtain the very majority of the most stable isomers of the complex of formula (II).
- the method according to the invention has been defined in the claims. Although the following description may for information include material going beyond the scope of the invention, this scope and therefore also the scope of protection remain limited to the subject matter defined by the claims.
- the process for preparing the complex of formula (II) developed by the inventors is based on a step of isomeric enrichment of the gadolinium complex of intermediate hexaacid of formula (I) represented below:
- the complex of formula (I) corresponds to several stereoisomers, due to the presence of the three asymmetric carbon atoms located in the ⁇ position on the side chains of the complex, relative to the nitrogen atoms of the macrocycle on which the said side chains are grafted. . These three asymmetric carbons are marked with an asterisk (*) in formula (I) shown above.
- each of the 3 asymmetric carbons carrying a carboxylate function can be of absolute configuration R or S
- the complex of formula (I) exists in the form of 8 stereoisomers, referred to below as I-RRR, I-SSS, I -RRS, I-SSR, I-RSS, I-SRR, I-RSR and I-SRS. More precisely, according to the usual nomenclature in stereochemistry, the complex of formula (I) exists in the form of 4 pairs of enantiomers, diastereoisomers between them.
- HPLC high performance liquid phase chromatography
- UHPLC ultra high performance liquid phase chromatography
- IsoD crystallizes in water.
- X-ray diffraction analyzes enabled the inventors to determine the crystalline structure of this group of isomers, and thus to discover that it comprises the I-RRR and I-SSS diastereoisomers of the complex of formula (I), of formulas (I-RRR) and (I-SSS) shown below.
- the isomeric enrichment step of the process of the invention aims to enrich the gadolinium complex with the intermediate hexaacid of formula (I) in isoD.
- the synthesis of the complex of formula (II) notably involves a conversion of the carboxylic acid functions of the intermediate hexaacid complex of formula (I) into an amide function. This amidation reaction does not modify the absolute configuration of the three asymmetric carbon atoms of the complex of formula (I).
- Gadolinium complex of hexaacid of formula (I) Gadolinium complex of hexaacid of formula (I)
- the process according to the invention therefore involves the hexaacid gadolinium complex of formula (I): consisting of at least 80% of a diastereoisomeric excess comprising a mixture of I-RRR and I-SSS isomers of formulas:
- diastereoisomeric excess is intended to denote, in the context of the present invention, and with regard to the complex of gadolinium of hexaacid of formula (I), the fact that said complex is mainly present in the form of an isomer or group of isomers chosen from among the diastereoisomers I-RRR, I-SSS, I-RRS, I-SSR, I-RSS, I-SRR, I-RSR and I-SRS.
- Said diastereoisomeric excess is expressed as a percentage, and corresponds to the quantity represented by the predominant isomer or group of isomers relative to the total quantity of the gadolinium complex of hexaacid of formula (I). It is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
- the complex of formula (I) has at least 85%, in particular at least 90%, in particular at least 95%, preferably at least 97%, advantageously at least 98 %, more preferably at least 99% of the diastereoisomeric excess comprising the mixture of I-RRR and I-SSS isomers.
- said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
- said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
- mixture of I-RRR and I-SSS isomers also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present.
- mixture of I-RRR and I-SSS isomers preferably designates all the cases where each of the I-RRR and I-SSS isomers is present in a variable but non-zero amount.
- the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60 , in particular between 55/45 and 45/55.
- the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
- the diastereoisomeric excess as defined previously corresponds to peak 4 of the HPLC trace (that is to say the fourth peak in the order of elution and corresponding to isoD), characterized by a retention time comprised between 33.9 and 37.5 minutes, typically about 35.7 minutes, said trace being obtained by implementing the HPLC method described below.
- HPLC trace is meant, within the meaning of the present invention, the profile of the concentrations measured by the detector after passage and separation of a mixture of compounds (in this case isomers of a compound) on a phase stationary as a function of time for a given composition and eluent flow rate.
- the HPLC trace is made up of different peaks or peaks characteristic of the compound or mixture of compounds analyzed.
- diastereoisomeric excess is meant, in the context of the present invention, and with regard to the complex of formula (II), the fact that said complex is mainly present in the form of an isomer or group of isomers chosen from among diastereoisomers II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS.
- Said diastereoisomeric excess is expressed as a percentage and corresponds to the quantity represented by the predominant isomer or group of isomers relative to the total quantity of the complex of formula (II). It is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
- the complex of formula (II) obtained by the process according to the invention has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94%, advantageously at least at least 97%, more preferably at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
- said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
- said diastereoisomeric excess consists of the mixture of II-RRR and II-SSS isomers.
- mixture of II-RRR and II-SSS isomers also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present.
- mixture of II-RRR and II-SSS isomers preferably designates the whole cases where each of the II-RRR and II-SSS isomers is present in a variable but non-zero amount.
- the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60 , in particular between 55/45 and 45/55.
- the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
- the diastereoisomeric excess as defined above corresponds to peak 4 of the UHPLC trace (i.e. the fourth mass of isomers in the order of elution and corresponding to iso4), characterized by a time retention of between 6.0 and 6.6 minutes, typically about 6.3 minutes, said trace being obtained by implementing the UHPLC method described below.
- UHPLC trace is meant, within the meaning of the present invention, the profile of the concentrations measured by the detector after passage and separation of a mixture of compounds (in this case isomers of a compound) on a phase stationary as a function of time for a given composition and eluent flow rate.
- the UHPLC trace consists of different peaks or peaks characteristic of the compound or mixture of compounds analyzed.
- This is a reverse phase UPLC column with spherical particles consisting of a core, preferably very hard, in silica surrounded by a porous silica with a trifunctional C18 (octadecyl) grafting, and whose silanols have been treated with styling agents (end-capped). It is also characterized by a length of 150 mm, an internal diameter of 2.1 mm, a grain size of 1.6 ⁇ m, a porosity of 120 ⁇ and a carbon content of 4.7%.
- the stationary phase used must be compatible with the aqueous mobile phases.
- - analysis conditions Sample Aqueous solution of the complex of formula (II) at 2.0 mg/mL Column temperature 40°C Sample temperature Ambient temperature (20-25°C) Debit 0.3mL/min injection volume 1 ⁇ L UV detection 200nm - mobile phase gradient (% v /v): Time (mins) Acetonitrile (100%) H 2 SO 4 (0.0005% v/v aqueous solution) 0 1 99 3 5 95 12 10 90
- the complex of formula (II) is obtained by amidation from the complex of formula (I) as defined above and 3-amino-1,2-propanediol, in racemic form or enantiomerically pure, preferably in racemic form.
- Such a reaction can in particular be carried out after activation of the carboxylic acid functions, as is detailed in the remainder of the description.
- Gd gadolinium
- Gd 3+ gadolinium oxide
- free Gd denotes the uncomplexed forms of gadolinium, and preferably available for complexation. This is typically the water-solubilized Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide.
- step a) comprises the reaction between the hexaacid of formula (III) and a source of free Gd in water.
- the source of free Gd is GdCl 3 or Gd 2 O 3 , preferably Gd 2 O 3 .
- the reagents used in step a) that is to say the source of gadolinium (typically gadolinium oxide), the hexaacid of formula (III) and water, are the purest. possible, especially with regard to metallic impurities.
- the source of gadolinium will advantageously be gadolinium oxide, preferably with a purity greater than 99.99%, and even more preferably greater than 99.999%.
- the water used in the process preferably comprises less than 50 ppm calcium, more preferably less than 20 ppm, and most preferably less than 15 ppm calcium.
- the water used in the process is deionized water, water for injection (water for injection) or purified water.
- the quantities of the reagents correspond to, or are close to, stoichiometric proportions, as dictated by the equation-balance of the reaction of complexation taking place during this step.
- stoichiometric proportions By “close to stoichiometric proportions”, is meant that the difference between the molar proportions in which the reactants are introduced and the stoichiometric proportions is less than 15%, in particular less than 10%, preferably less than 8%.
- the gadolinium can in particular be introduced in a slight excess with respect to the stoichiometric proportions.
- the ratio of the amount of material introduced in gadolinium to the amount of material introduced in hexaacid of formula (III) is then greater than 1, but typically less than 1.15, in particular less than 1.10, advantageously less than 1.08 .
- the amount of gadolinium introduced is greater than 1 equivalent (eq.), but typically less than 1.15 eq., in particular less than 1.10 eq., advantageously less than 1.08 eq., relative to the amount of hexaacid of formula (III) introduced, which for its part corresponds to 1 equivalent.
- the quantity of Gd 2 O 3 introduced is then typically greater than 0.5 eq., but less than 0.575 eq., in particular less than 0, 55 eq., advantageously less than 0.54 eq., relative to the quantity of hexaacid of formula (III) introduced (1 eq.).
- the content of hexaacid of formula (III) in the aqueous solution prepared during step a1) is typically between 10% and 60%, in particular between 15% and 45%, preferably between 20% and 35%, advantageously between 25% and 35%, even more advantageously between 25% and 30% by weight relative to the total weight of the aqueous solution.
- steps a) and b) are carried out according to a one-pot embodiment, that is to say in the same reactor and without an intermediate step of isolation or purification.
- the hexaacid gadolinium complex of formula (I) formed during step a) is directly subjected to step b) of isomerization, without being isolated or purified, and in the same reactor as that used for step a).
- the gadolinium complex of hexaacid of formula (I) formed by the complexation reaction between the hexaacid of formula (III) and gadolinium during step a) is initially obtained in the form of a mixture of diastereoisomers .
- Step b) aims to enrich the mixture of diastereoisomers in the I-RRR and I-SSS isomers, to obtain the complex of gadolinium of hexaacid of formula (I) diastereoisomerically enriched consisting of at least 85%, in particular of at least 90%, in particular at least 95%, preferably at least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of isomers I -RRR and I-SSS.
- formula (I) diastereoisomerically enriched consisting of at least 85%, in particular of at least 90%, in particular at least 95%, preferably at least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of isomers I -RRR and I-SSS.
- said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
- said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
- the inventors have in fact discovered that factors such as the pH and the temperature of the solution of gadolinium complex of hexaacid of formula (I) obtained at the end of step a) have an influence on the ratio in which the various isomers of the complex of formula (I) are present within the mixture of diastereoisomers. Over time, the mixture tends to be enriched in a group of isomers comprising the isomers which are, surprisingly, the most stable thermodynamically but also chemically, in this case the I-RRR and I-SSS isomers.
- mixture of I-RRR and I-SSS isomers also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present.
- mixture of I-RRR and I-SSS isomers preferably designates all the cases where each of the I-RRR and I-SSS isomers is present in a variable but non-zero amount.
- the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/ 45 and 45/55.
- the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
- Step b) of isomerization of the hexaacid gadolinium complex of formula (I) in an aqueous solution is typically carried out at a pH of between 2 and 4, in particular between 2 and 3, advantageously between 2.2 and 2, 8.
- the pH is preferably adjusted with an acid, preferably an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, for example with hydrochloric acid .
- an acid preferably an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, for example with hydrochloric acid .
- Step b) is typically carried out at a temperature between 80°C and 130°C, in particular between 90°C and 125°C, preferably between 98°C and 122°C, advantageously between 100°C and 120°C. C, typically for a period of between 10h and 72h, in particular between 10h and 60h, advantageously between 12h and 48h.
- the aqueous solution of step b) comprises acetic acid.
- Step b) is then advantageously carried out at a temperature of between 100°C and 120°C, in particular between 110°C and 118°C, typically for a period of between 12 h and 48 h, in particular between 20 h and 30 h, in particular between 24h and 26h.
- the acetic acid is preferably added before heating the solution of gadolinium hexaacid complex of formula (I) obtained during step a) in an amount such that the acetic acid content is between 25% and 75%, in particular between 40% and 50% by mass relative to the mass of hexaacid of formula (III) used during step a).
- acetic acid is added as the water evaporates, so as to maintain a constant volume of solution.
- the diastereoisomerically enriched complex is isolated by crystallization, preferably by crystallization by seeding.
- Step b2) of crystallization aims on the one hand to eliminate any impurities present in the aqueous solution, which may result from previous steps, so as to obtain a product of greater purity, discolored, in the form of crystals, and on the other hand to continue the diastereoisomeric enrichment of the gadolinium complex of hexaacid of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said complex greater than that obtained at the result of step b1).
- the I-RRR and I-SSS isomers of the hexaacid complex of formula (I) crystallize in water.
- the hexaacid gadolinium complex of formula (I) not enriched in said isomers does not crystallize.
- the crystallization in water of the isomers of interest of the gadolinium complex of hexaacid of formula (I) makes it possible to avoid adding a solvent as described in example 7 of the document EP 1 931 673 , which involves a step of precipitation in ethanol of the trisodium salt of said complex.
- Stage b2) is advantageously carried out at a temperature of between 10°C and 70°C, in particular between 30°C and 65°C, in particular between 35° and 60°C.
- Crystallization by seed also called “crystallization by seed” includes the introduction into the reactor in which the crystallization is carried out (also called crystallizer) of a known quantity of crystals, called “seed” or “starter”. This reduces the crystallization time. Seed crystallization is well known to those skilled in the art.
- the seeding by use of a primer in this case crystals of gadolinium complex of diastereoisomerically enriched hexaacid of formula (I) added to the aqueous solution of the diastereoisomerically enriched complex whose temperature has been previously lowered, makes it possible to obtain nucleation, and thus to initiate crystallization.
- the duration of the crystallization by seeding is advantageously between 2 h and 20 h, preferably between 6 h and 18 h, typically, it is 16 h.
- crystals of diastereoisomerically enriched hexaacid gadolinium complex of formula (I) are then typically isolated by filtration and drying, using any technique well known to those skilled in the art.
- the degree of purity of the diastereoisomerically enriched gadolinium hexaacid complex of formula (I) isolated at the end of step b2) is greater than 95%, in particular greater than 98%, advantageously greater than 99%, said degree of purity being expressed as a mass percentage of the complex of formula (I) relative to the total mass obtained at the end of step b2).
- the diastereoisomerically enriched complex of step b) isolated by crystallization is again purified by recrystallization, to obtain a diastereoisomerically enriched and purified complex.
- step b) comprises, in addition to the successive steps b1) and b2) previously described, a step b3) of purification by recrystallization of the isolated diastereoisomerically enriched gadolinium hexaacid complex of formula (I).
- Step b3) of recrystallization aims, like step b2) of crystallization, on the one hand, to obtain a product of greater purity, and, on the other hand, to continue the diastereoisomeric enrichment of the hexaacid gadolinium complex of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said complex greater than that obtained at the end of step b2).
- the degree of purity of the purified diastereoisomerically enriched gadolinium hexaacid complex of formula (I) isolated at the end of step b3) is typically greater than 98%, in particular greater than 99%, advantageously greater than 99.5% , said degree of purity being expressed as a mass percentage of the complex of formula (I) relative to the total mass obtained at the end of step b2).
- the diastereoisomerically enriched complex of step b) is further enriched by selective decomplexation of the diastereoisomers of the complex of formula (I) other than the I-RRR and I-SSS diastereoisomers, i.e. by selective decomplexation of the diastereoisomers I-RSS, I-SRR, I-RSR, I-SRS, I-RRS and I-SSR.
- step b) comprises, in addition to the successive steps b1) and b2) previously described, a step b4) of selective decomplexation of the diastereoisomers of the complex of formula (I) other than the diastereoisomers I-RRR and I -SSS.
- step b) can also comprise step b3) previously described, said step b3) being implemented between steps b2) and b4), or after step b4).
- Step b4) of selective decomplexation aims to continue the diastereoisomeric enrichment of the complex of gadolinium with the hexaacid of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said higher complex to that obtained at the end of step b2) or at the end of step b3), when the latter is implemented prior to step b4).
- Step b4) is made possible by the fact that the I-RRR and I-SSS isomers are the most stable in a basic medium.
- Such basic conditions favor the formation of gadolinium hydroxide, and consequently the decomplexation of the less stable isomers.
- the I-RRR and I-SSS isomers are more stable both in an acid medium, which allows step b1) of isomerization, and in a basic medium, which allows step b4) of selective decomplexation.
- the diastereoisomerically enriched complex obtained at the end of step b) according to any one of the variants described above has at least 85%, in particular at least 90%, in particular at least 95 %, preferably at least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of I-RRR and I-SSS isomers.
- said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
- said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
- mixture of I-RRR and I-SSS isomers also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present. Nevertheless, the term “mixture of I-RRR and I-SSS isomers” preferably designates all the cases where each of the I-RRR and I-SSS isomers is present in a variable but non-zero amount.
- the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/ 45 and 45/55.
- the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
- Step c) aims to form the complex of formula (II) from its precursor, the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) obtained during step b).
- the three carboxylic acid functions of the hexaacid complex of formula (I) carried by the carbon atoms located in the ⁇ position on the side chains of the complex, relative to the nitrogen atoms of the macrocycle on which the said side chains, are converted into amide functions, by amidation reaction with 3-amino-1,2-propanediol, in racemic or enantiomerically pure form, preferably in racemic form.
- step c) makes it possible to obtain the complex of formula (II) with a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers identical to the diastereoisomeric excess comprising a mixture of I-RRR isomers and I-SSS with which is obtained the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) obtained at the end of step b), which is at least 80%.
- the complex of formula (II) obtained at the end of step c) has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94% , advantageously at least 97%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
- said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
- said diastereoisomeric excess consists of the mixture of II-RRR and II-SSS isomers.
- mixture of II-RRR and II-SSS isomers also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present.
- mixture of II-RRR and II-SSS isomers preferably designates all the cases where each of the II-RRR and II-SSS isomers is present in a variable but non-zero amount.
- the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/ 45 and 45/55.
- the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
- amidation reaction can be carried out according to any method well known to those skilled in the art, in particular in the presence of an agent which activates carboxylic acid functions and/or in acid catalysis.
- said carboxylic acid functions can in particular be activated in the form of ester functions, acyl chlorides, acid anhydrides, or in any activated form capable of leading to an amide bond.
- the activated forms capable of leading to an amide bond are well known to those skilled in the art. profession and can for example be obtained by all the methods known in peptide chemistry to create a peptide bond.
- step c) comprises the activation of the carboxylic acid functions (-COOH) mentioned above in the form of ester, acyl chloride or acid anhydride functions.
- This embodiment is preferred to peptide coupling by activation of the carboxylic acid function using a coupling agent such as EDCI/HOBT as described in the document EP 1 931 673 .
- a coupling agent such as EDCI/HOBT as described in the document EP 1 931 673 .
- a coupling agent such as EDCI/HOBT as described in the document EP 1 931 673 .
- such a coupling leads to the formation of an equivalent of 1-ethyl-3-[3-(dimethylamino)propyl]urea, which must be eliminated, in particular by chromatography on silica or by liquid/liquid extraction by adding a solvent .
- the implementation of such purification methods is not desirable, as discussed above.
- the use of HOBT is in itself problematic, in that it is an explosive product.
- ester function is meant, within the meaning of the present invention, a —C(O)O— group. It may in particular be a —C(O)OR 1 group, in which R 1 corresponds to a (C 1 -C 6 )alkyl group.
- (C 1 -C 6 )alkyl group is meant, within the meaning of the present invention, a saturated hydrocarbon chain, linear or branched, comprising 1 to 6, preferably 1 to 4, carbon atoms.
- a saturated hydrocarbon chain linear or branched, comprising 1 to 6, preferably 1 to 4, carbon atoms.
- acyl chloride function also called “acid chloride function” is meant within the meaning of the present invention a —CO—CI group.
- acid anhydride function is meant, within the meaning of the present invention, a —CO—O—CO— group. It may in particular be a —CO—O—CO—R 2 group, in which R 2 corresponds to a (C 1 -C 6 )alkyl group.
- the complex of formula (II) is then obtained by aminolysis of the carboxylic acid functions activated in the form of ester functions, acyl chlorides or acid anhydrides, in particular esters or acid anhydrides, preferably esters, by reaction with the 3-Amino-1,2-propanediol, in racemic or enantiomerically pure form, preferably in racemic form.
- the steps of activating the carboxylic acid functions and of aminolysis are carried out according to a one-pot embodiment, that is to say in the same reactor and without step intermediate for isolating or purifying the intermediate comprising the carboxylic acid functions activated in the form of esters, acyl chlorides or acid anhydrides, in particular esters or acid anhydrides, preferably esters.
- the formation reaction of the activated complex of formula (VII) does not modify the absolute configuration of the three asymmetric carbon atoms located in position ⁇ on the side chains, with respect to the atoms of macrocycle nitrogen on which said side chains are grafted.
- step c1) makes it possible to obtain the activated complex of formula (VII) with a diastereoisomeric excess comprising a mixture of the VII-RRR and VII-SSS isomers, of formulas (VII-RRR) and (VII-SSS) represented below, identical to the diastereoisomeric excess comprising a mixture of I-RRR and I-SSS isomers with which is obtained the complex of gadolinium of hexaacid of formula (I) diastereoisomerically enriched obtained at the end of step b), which is at least 80%.
- step c1) is typically carried out by reaction between the gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched obtained during step b) and thionyl chloride (SOCl 2 ).
- step c1) is typically carried out by reaction between the diastereoisomerically enriched gadolinium complex of hexaacid of formula (I) obtained during step b) and acetyl chloride.
- step c) comprises the activation of the carboxylic acid functions (-COOH) mentioned above in the form of ester functions.
- Step c1) is typically carried out in the alcohol of formula R 1 OH, which plays both the role of solvent and reagent, in the presence of an acid such as hydrochloric acid.
- the hexaacid gadolinium complex of formula (I) and the alcohol R 1 OH are loaded into the reactor.
- the reaction medium is then cooled to a temperature below 10°C, in particular below 5°C, typically at 0°C, and an acid solution of the alcohol R 1 OH, typically of hydrochloric acid in R 1 OH is then gradually added.
- the reaction medium is kept stirred at room temperature (that is to say at a temperature between 20 and 25° C.) for a period typically greater than 5 hours, preferably between 10 hours and 20 hours.
- the reaction medium is cooled at a temperature below 10° C., in particular between 0° C. and 5° C., prior to step c2).
- Step c2) is also typically carried out in the alcohol of formula R 1 OH, in the presence of an acid such as hydrochloric acid.
- steps c1) and c2) can easily be implemented according to a one-pot embodiment.
- the triester of formula (VII) is not isolated between steps c1) and c2).
- step c2) the alcohol of formula R 1 OH is preferably removed by vacuum distillation.
- vacuum distillation is meant, within the meaning of the present invention, the distillation of a mixture carried out at a pressure of between 10 and 500 mbar, in particular between 10 and 350 mbar, preferably between 10 and 150 mbar, in particular between 50 and 100 mbar.
- 3-amino-1,2-propanediol is introduced in large excess.
- the amount of material of 3-amino-1,2-propanediol introduced is greater than 4 eq., in particular greater than 7 eq., advantageously greater than 10 eq., relative to the amount of material of gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched initially introduced during step c), which corresponds to 1 equivalent.
- the methyl triester of formula (IV) is not isolated between steps c1) and c2).
- step c2) the methanol is removed by distillation under vacuum, until a temperature typically greater than 55° C., in particular between 60° C. and 65° C., is reached, and the reaction medium is maintained at this temperature under vacuum for a period typically greater than 5 h, in particular between 10 h and 20 h, before being cooled to ambient temperature and diluted with water.
- the present invention encompasses all the combinations of the particular, advantageous or preferred embodiments described above in connection with each step of the method.
- the process according to the invention therefore involves a triester gadolinium complex of formula (VIII): consisting of at least 80% of a diastereoisomeric excess comprising a mixture of VIII-RRR and VIII-SSS isomers of formulas:
- diastereoisomeric excess is meant, in the context of the present invention, and with regard to the triester gadolinium complex of formula (VIII), the fact that said complex is predominantly present in the form of an isomer or group of isomers chosen from the VIII-RRR, VIII-SSS, VIII-RRS, VIII-SSR, VIII-RSS, VIII-SRR, VIII-RSR and VIII-SRS diastereoisomers.
- Said diastereoisomeric excess is expressed as a percentage, and corresponds to the quantity represented by the predominant isomer or group of isomers relative to the total quantity of the triester complex of formula (VIII). He is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
- the triester gadolinium complex of formula (VIII) according to the invention has at least 85%, in particular at least 90%, in particular at least 95%, preferably at least least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of VIII-RRR and VIII-SSS isomers.
- said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of isomers VIII-RRR and VIII- SSS.
- said diastereoisomeric excess consists of the mixture of VIII-RRR and VIII-SSS isomers.
- mixture of VIII-RRR and VIII-SSS isomers also covers the case where only one of the isomers, whether it be VIII-RRR or VIII-SSS, is present.
- mixture of VIII-RRR and VIII-SSS isomers preferably designates all the cases where each of the VIII-RRR and VIII-SSS isomers is present in a variable but non-zero quantity.
- the VIII-RRR and VIII-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60 , in particular between 55/45 and 45/55.
- the mixture of VIII-RRR/VIII-SSS isomers is a racemic mixture (50/50).
- the triester gadolinium complex of formula (VIII) is a trimethyl gadolinium complex, that is to say a triester gadolinium complex of formula (VIII) in which R 1 is a methyl group (CH 3 ).
- the hexaacid of formula (III), which occurs during step a) of the process for preparing the complex of formula (II) according to the invention, can be prepared according to any method already known and in particular according to the methods described in the patent EP 1 931 673 .
- R 3 and R 4 are identical.
- the hexaacid of formula (III) is obtained by alkylation of the pyclene of formula (V): with dibutyl 2-bromoglutarate, to obtain the butyl hexaester of formula (VI): followed by a hydrolysis step, leading to said hexaacid of formula (III).
- the dibutyl 2-bromoglutarate used is in racemic or enantiomerically pure form, preferably in racemic form.
- dibutyl 2-bromoglutarate is particularly advantageous, in comparison with that of ethyl 2-bromoglutarate described in the document EP 1 931 673 .
- commercial diethyl 2-bromoglutarate is a relatively unstable compound, which degrades over time and under the effect of temperature. More specifically, this ester tends to hydrolyze or cyclize and therefore to lose its bromine atom. Attempts to purify commercial diethyl 2-bromoglutarate, or to develop new synthetic routes allowing it to be obtained with improved purity, and thus prevent its degradation, have been unsuccessful.
- the alkylation reaction is typically carried out in a polar solvent, preferably in water, in particular in deionized water, advantageously in the presence of a base such as potassium or sodium carbonate.
- a polar solvent preferably in water, in particular in deionized water, advantageously in the presence of a base such as potassium or sodium carbonate.
- the reaction is advantageously carried out at a temperature between 40° C. and 80° C., typically between 50° C. and 70° C., in particular between 55° C. and 60° C., for a period of between 5 h and 20 h, in particular between 8 a.m. and 3 p.m.
- the hydrolysis step is advantageously carried out in the presence of an acid or a base, advantageously a base such as sodium hydroxide.
- the hydrolysis solvent can be water, an alcohol such as ethanol, or a water/alcohol mixture. This step is advantageously carried out at a temperature of between 40°C and 80°C, typically between 40°C and 70°C, in particular between 50°C and 60°C, typically for a period of between 10h and 30h, in particular between 3 p.m. and 10 p.m.
- the process according to the invention therefore involves the butyl hexaester of formula (VI):
- this hexaester is distinguished by a markedly improved stability compared to esters having a shorter alkyl chain, in particular compared to the ethyl hexaester described in the document EP 1 931 673 .
- FIGURES are a diagrammatic representation of FIGURES.
- Figure 1 degradation under basic conditions of the groups of iso1 to iso4 isomers of the complex of formula (II), expressed as surface percentage of a given group of isomers over time.
- An HPLC apparatus consisting of a pumping system, an injector, a chromatographic column, a UV spectrophotometric detector and a control and data processing station is used.
- the chromatographic column used is a C18 column - 250 ⁇ 4.6 mm - 5 ⁇ m (Symmetry® range , from Waters).
- Route A 100% acetonitrile and Route B: aqueous solution of H2SO4 (96%) at 0.1% v/v
- Peak 4 of the HPLC trace namely the isoD, corresponds to a retention time of 35.7 minutes.
- a UHPLC apparatus consisting of a pumping system, an injector, a chromatographic column, a UV detector and a data station is used.
- the chromatographic column used is a 150 ⁇ 2.1 mm ⁇ 1.8 ⁇ m UHPLC column (ACQUITY UPLC HSS T3 column from Waters). It is a reversed-phase UPLC column with spherical particles made of silica with a trifunctional C18 (octadecyl) grafting, and whose silanols have been treated with capping agents (end-capped). It is further characterized by a length of 150 mm, an internal diameter of 2.1 mm, a particle size of 1.8 ⁇ m, a porosity of 100 ⁇ and a carbon content of 11%.
- the stationary phase used must be compatible with the aqueous mobile phases.
- - Moving phase Route A: 100% acetonitrile and Route B: aqueous solution of H 2 SO 4 (96%) at 0.1% v/v -
- Preparation of test solutions Solution of the hexaacid gadolinium complex of formula (I) at 0.8 mg/mL in purified water - Analysis conditions : Column temperature 35°C Sample temperature Ambient temperature (20-25°C) Debit 0.4mL/min injection volume 10 ⁇ l UV detection 200nm Analysis time 32 mins - Gradient : Time % Acne % H 2 SO 4 0.1% 0 1 99 14 8 92 20 11 89 25 25 75 27 1 99 32 1 99
- Peak 4 of the UHPLC trace namely the isoD, corresponds to a retention time of 17.4 minutes.
- a UHPLC apparatus consisting of a pumping system, an injector, a chromatographic column, a UV detector and a data station is used.
- the chromatographic column used is a 150 ⁇ 2.1 mm ⁇ 1.6 ⁇ m UHPLC column ( CORTECS® UPLC T3 column from Waters).
- Peak 4 of the UHPLC trace namely iso4, corresponds to a retention time of 6.3 minutes.
- the relaxation times T 1 and T 2 were determined by standard procedures on a Minispec ® mq20 apparatus (Bruker) at 20 MHz (0.47 T), at 60 MHz (1.41 T) and 37°C.
- the longitudinal relaxation time T 1 is measured using an Inversion Recovery sequence and the transverse relaxation time T 2 is measured by a CPMG (Carr-Purcell-Meiboom-Gill) technique.
- the correlation between R 1 or R 2 as a function of the concentration is linear, and the slope represents the relaxivity r 1 (R 1 /C) or r 2 (R 2 /C) expressed in (1 / second) x (1/ mMole/L) or (mM -1 .s -1 ).
- T 1/2 The half-life times (T 1/2 ) which were determined for each of the groups of isomers are given in the table below: Isomer groups T 1/2 (pH 1.2 - 37°C) Iso1 18 hours Iso2 6 hours Iso3 8 days Iso4 27 days
- the degradation kinetics of the blocks of iso1 to iso4 isomers are evaluated by measuring the HPLC purity and by monitoring the area of each block of isomers over time. The quantities measured are thus: - P HPLC (time), and Area IsoX you Area IsoX you 0
- the butyl hexaester is reextracted in the toluene phase by dilution with 145 kg of toluene and 165 kg of water followed by basification with 30% (m/m) soda to reach a pH of 5-5.5.
- the lower aqueous phase is removed.
- the butyl hexaester is obtained by concentration to dryness under vacuum at 60° C. with a yield of approximately 85%.
- Gadolinium oxide (0.525 molar eq.) is suspended in a solution of hexaacid of formula (III) at 28.1% by weight.
- the 99-100% acetic acid (50% by mass/pure hexaacid of formula (III)) is poured onto the medium at room temperature.
- the medium is heated to reflux and then distilled to 113° C. by mass, reloading the medium with acetic acid as the water is eliminated. Arrived at 113° C., a sufficient quantity of acetic acid is added in order to arrive at the starting volume.
- the medium is maintained at 113° C. overnight.
- the hexaacid gadolinium complex of formula (I) in solution is cooled to 40° C., the primer is added, the mixture is left in contact for at least 2 hours. It is then isolated by filtration at 40° C. and washed with osmosed water.
- the dry product is charged to the reactor with osmosis water at 20°C.
- the mass of water added is equal to twice the mass of gadolinium hexaacid complex of theoretical formula (I).
- 30.5% (m/m) sodium hydroxide (6.5 eq) is poured onto the medium at 20°C.
- the medium is left in contact at 50° C. at the end of the addition of NaOH for 16:00.
- the medium is cooled to 25° C. and the product filtered through a bed of Clarcel.
- the ratio in which the different isomers of the complex of formula (I) are present within the mixture of diastereoisomers depends on the conditions under which the complexation and isomerization steps are carried out, as shown in Table 3 below.
- Table 3 Table 3 ⁇ /u>: content of the I-RRR and I-SSS mixture as a function of the complexation / isomerization conditions pH Temperature Content of hexaacid of formula (III) Duration Diastereoisomeric excess comprising a mixture of I-RRR and I-SSS 5.7 80°C 40% 3h 19% 3.5 90°C 50% 10am 49% 3.0 101°C 40% 10am 68% 2.7 101°C 28% 48h 98.04%
- the medium is diluted with 607 kg of water while cooling to ambient temperature.
- the solution of the crude complex of formula (II) is neutralized with 20% (m/m) hydrochloric acid. 978.6 kg of solution are thus obtained, with a concentration of 10.3%, representing 101 kg of material.
- the yield obtained is 86.5%.
- an HCl solution at pH 3 is prepared by diluting 1 mL of 1N HCl in 1 liter of water. The isomers are added at a concentration of 1 mM in the HCl solution at pH 3. 10 mg of powder are dissolved in 10 mL of this solution. The 8 solutions obtained are heated to 100° C. and then analyzed at T 0 and at T 0 +23 hours by HPLC.
- the loss of purity is due to the chemical degradation (hydrolysis of the amide functions) of the product due to the conditions imposed by the isomerization reaction.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
La présente invention a trait à un nouveau procédé de synthèse d'un complexe de gadolinium et d'un ligand chélateur dérivé de PCTA, qui permet d'obtenir de manière préférentielle les stéréoisomères dudit complexe qui présentent des propriétés physico-chimiques tout particulièrement intéressantes pour des applications en tant qu'agent de contraste dans le domaine de l'imagerie médicale, notamment pour l'Imagerie par Résonance Magnétique.The present invention relates to a new process for the synthesis of a complex of gadolinium and a chelating ligand derived from PCTA, which makes it possible to preferentially obtain the stereoisomers of said complex which have physicochemical properties which are particularly advantageous for applications as a contrast agent in the field of medical imaging, in particular for Magnetic Resonance Imaging.
On connaît de nombreux agents de contraste à base de chélates de lanthanides (métal paramagnétique), en particulier de gadolinium (Gd), décrits par exemple dans le brevet
D'autres produits, dont certains sont en cours de développement, représentent une nouvelle génération de GBCA. Il s'agit essentiellement de complexes de chélates macrocycliques, tels que les complexes de l'acide bicyclopolyazamacrocyclocarboxylique (
Les complexes de ligands chélateurs dérivés de
Dans l'organisme, les chélates (ou complexes) de lanthanide - et notamment de gadolinium - sont en situation d'équilibre chimique (caractérisé par sa constante thermodynamique Ktherm), ce qui peut conduire à une libération non souhaitée dudit lanthanide (voir équation 1 ci-après) :
Depuis 2006, une pathologie appelée NSF (Nephrogenic Systemic Fibrosis, fibrose néphrogénique systémique ou dermopathie fibrogénique), a été reliée, au moins en partie, à la libération de gadolinium libre dans l'organisme. Cette maladie a conduit à une alerte des autorités de santé vis-à-vis d'agents de contraste gadolinés commercialisés pour certaines catégories de patients.Since 2006, a pathology called NSF (Nephrogenic Systemic Fibrosis, systemic nephrogenic fibrosis or fibrogenic dermopathy), has been linked, at least in part, to the release of free gadolinium in the body. This disease led to an alert from the health authorities regarding gadoline contrast agents marketed for certain categories of patients.
Des stratégies ont donc été mises en place pour résoudre de manière complètement sécurisée le problème complexe de la tolérance chez le patient, et limiter, voire éliminer, le risque de libération de lanthanide non souhaitée après administration. Ce problème est d'autant plus délicat à résoudre que l'administration d'agents de contraste est souvent répétée, que ce soit lors d'examens de diagnostic, ou pour l'ajustement des doses et le suivi de l'efficacité d'un traitement thérapeutique.Strategies have therefore been put in place to solve the complex problem of patient tolerance in a completely safe manner, and to limit, or even eliminate, the risk of unwanted lanthanide release after administration. This problem is all the more delicate to solve as the administration of contrast agents is often repeated, whether during diagnostic examinations, or for adjusting doses and monitoring the effectiveness of a therapeutic treatment.
En outre, depuis 2014 est évoqué un possible dépôt cérébral de gadolinium après administrations répétées de produits gadolinés, plus particulièrement de chélates de gadolinium linéaires, un tel dépôt n'ayant pas, ou peu, été rapporté avec les chélates macrocycliques de gadolinium, comme Dotarem® En conséquence, différents pays ont décidé soit de retirer la plupart des chélates linaires du marché, soit de limiter drastiquement leurs indications d'utilisation, compte tenu de leur stabilité estimée insuffisante.In addition, since 2014, a possible cerebral deposit of gadolinium has been mentioned after repeated administration of gadolinium products, more particularly linear gadolinium chelates, such a deposit having not, or only slightly, been reported with macrocyclic gadolinium chelates, such as Dotarem ® Consequently, various countries have decided either to withdraw most linear chelates from the market, or to drastically limit their indications for use, taking into account their stability deemed insufficient.
Une stratégie de limitation du risque de libération de lanthanide dans l'organisme consiste ainsi à opter pour des complexes qui se distinguent par des stabilités thermodynamique et/ou cinétique les plus élevées possible. En effet, plus le complexe est stable, plus la quantité de lanthanide libérée au cours du temps sera limitée.A strategy for limiting the risk of release of lanthanide in the organism thus consists in opting for complexes which are distinguished by the highest possible thermodynamic and/or kinetic stability. Indeed, the more the complex is stable, the more the quantity of lanthanide released over time will be limited.
Or, les complexes de ligands chélateurs dérivés de PCTA comprenant une structure de type pyclène décrits dans le document
C'est notamment le cas du complexe de formule (II) représentée ci-après :
En effet, comme cela est notamment décrit dans le document
Il convient toutefois de noter que le complexe de formule (II) correspond à plusieurs stéréoisomères, notamment du fait de la présence des trois atomes de carbones asymétriques situés en position α sur les chaînes latérales du complexe, par rapport aux atomes d'azote du macrocycle sur lesquels sont greffées lesdites chaînes latérales. Ces trois carbones asymétriques sont marqués d'un astérisque (*) dans la formule (II) représentée ci-dessus.It should however be noted that the complex of formula (II) corresponds to several stereoisomers, in particular due to the presence of the three asymmetric carbon atoms located in position α on the side chains of the complex, with respect to the nitrogen atoms of the macrocycle on which said side chains are grafted. These three asymmetric carbons are marked with an asterisk (*) in formula (II) shown above.
Ainsi, la synthèse du complexe de formule (II) telle que décrite dans le document
Les groupements aminopropanediol des chaînes latérales du complexe de formule (II) comportent également un carbone asymétrique. Ainsi, le complexe de formule (II) comprend au total 6 carbones asymétriques, et existe par conséquent sous la forme de 64 stéréoisomères de configuration. Toutefois, dans la suite de la description, la seule source de stéréoisomérie considérée pour une chaîne latérale donnée sera, par souci de simplification, celle correspondant au carbone asymétrique portant le groupement carboxylate, marqué d'un astérisque (*) dans la formule (II) représentée ci-dessus.The aminopropanediol groups of the side chains of the complex of formula (II) also contain an asymmetric carbon. Thus, the complex of formula (II) comprises a total of 6 asymmetric carbons, and therefore exists in the form of 64 configurational stereoisomers. However, in the rest of the description, the only source of stereoisomerism considered for a given side chain will be, for the sake of simplification, that corresponding to the asymmetric carbon bearing the carboxylate group, marked with an asterisk (*) in the formula (II ) shown above.
Dans la mesure où chacun de ces 3 carbones asymétriques peut être de configuration absolue R ou S, le complexe de formule (II) existe sous la forme de 8 familles de stéréoisomères, dénommées ci-après II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR et II-SRS. Plus précisément, selon la nomenclature usuelle en stéréochimie, le complexe de formule (II) existe sous la forme de 8 familles de diastéréoisomères.Insofar as each of these 3 asymmetric carbons can be of absolute configuration R or S, the complex of formula (II) exists in the form of 8 families of stereoisomers, called hereinafter II-RRR, II-SSS, II- RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS. More precisely, according to the usual nomenclature in stereochemistry, the complex of formula (II) exists in the form of 8 families of diastereoisomers.
L'emploi du terme « famille » se justifie en cela que chacune de ces familles regroupe plusieurs stéréoisomères, notamment du fait de la présence d'un carbone asymétrique au sein du groupement aminopropanediol, comme évoqué précédemment.The use of the term “family” is justified in that each of these families groups together several stereoisomers, in particular due to the presence of an asymmetric carbon within the aminopropanediol group, as mentioned above.
Néanmoins, dans la mesure où, dans la suite de la description, la stéréoisomérie liée au carbone asymétrique d'un groupement aminopropanediol donné ne sera pas considérée, on parlera indifféremment d'isomères, stéréoisomères ou encore diastéréoisomères II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR et II-SRS, sans préciser que chacun correspond à une famille de stéréoisomères.Nevertheless, insofar as, in the remainder of the description, the stereoisomerism linked to the asymmetric carbon of a given aminopropanediol group will not be considered, reference will be made indiscriminately to isomers, stereoisomers or even diastereoisomers II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS, without specifying that each corresponds to a family of stereoisomers.
Les inventeurs sont parvenus à séparer et à identifier par chromatographie en phase liquide à haute performance (CLHP, plus communément désignée par l'acronyme anglais HPLC) et par chromatographie en phase liquide à ultra haute performance (CLUHP, plus communément désignée par l'acronyme anglais UHPLC) 4 massifs ou groupes d'isomères du complexe de formule (II) obtenu selon le procédé de l'art antérieur, correspondant à 4 pics d'élution différents caractérisés par leur temps de rétention sur le chromatogramme, que l'on nommera iso1, iso2, iso3 et iso4 dans la suite de la description. En mettant en œuvre le procédé décrit dans le document
Ils ont alors découvert que ces différents groupes d'isomères présentaient des propriétés physico-chimiques distinctes, et ont déterminé que le groupe d'isomères dénommé iso4, qui comprend un mélange des isomères II-RRR et II-SSS de formules (II-RRR) et (II-SSS) représentées ci-après, s'avère être le plus intéressant en tant qu'agent de contraste pour l'imagerie médicale.
Ainsi, l'iso4 se distingue, de façon étonnante, par une stabilité thermodynamique nettement supérieure à celle du mélange de diastéréoisomères sous la forme duquel est obtenu le complexe de formule (II) en mettant en œuvre le procédé décrit dans le document
De surcroît, l'iso4 est le groupe d'isomères qui présente la meilleure inertie cinétique (également appelée stabilité cinétique) parmi les quatre groupes isolés par les inventeurs. En effet, les inventeurs ont évalué l'inertie cinétique des quatre groupes d'isomères en étudiant leur cinétique de décomplexation en solution aqueuse acide (pH = 1,2), à 37°C. Les valeurs des temps de demi-vie (T1/2) qui ont été déterminées pour chacun des groupes d'isomères sont indiquées dans le tableau 1 ci-dessous, le temps de demi-vie correspondant à la durée au bout de laquelle 50 % de la quantité de complexe initialement présente a été dissociée, selon la réaction de décomplexation suivante (équation 2) :
A titre de comparaison, le gadobutrol ou le gadoterate, complexes macrocycliques de gadolinium, présentent respectivement une inertie cinétique de 18h et de 4 jours dans les mêmes conditions, tandis que les complexes linéaires de gadolinium comme le gadodiamide ou le gadopentetate se dissocient instantanément.By way of comparison, gadobutrol or gadoterate, macrocyclic gadolinium complexes, respectively show a kinetic inertia of 18 hours and 4 days under the same conditions, while linear gadolinium complexes such as gadodiamide or gadopentetate dissociate instantaneously.
En outre, l'iso4 est plus stable d'un point de vue chimique que l'iso3 notamment. Les fonctions amides du complexe de formule (II) sont en effet susceptibles d'être hydrolysées. La réaction d'hydrolyse d'une fonction amide (équation 3) aboutit à la formation d'une impureté dicouplée, qui s'accompagne de la libération de 3-amino-1,2-propanediol. Les inventeurs ont étudié la cinétique de la réaction d'hydrolyse du complexe de formule (II) en solution aqueuse à pH 13, et observé que les fonctions amides de l'iso4 sont plus stables vis-à-vis de l'hydrolyse que celles de l'iso3.
En ce qui concerne la relaxivité des différents groupes d'isomères, c'est-à-dire leur efficacité en tant qu'agent de contraste, les mesures réalisées mettent en évidence un pouvoir contrastant relativement équivalent pour les groupes iso1, iso2 et iso4, et une efficacité moindre pour l'iso3 (voir tableau 2).
Les inventeurs sont parvenus à développer un nouveau procédé de préparation du complexe de formule (II) permettant d'obtenir préférentiellement les diastéréoisomères II-RRR et II-SSS dudit complexe, qui présentent des propriétés physico-chimiques particulièrement avantageuses. Le procédé selon l'invention comprend une étape d'enrichissement isomérique, par conversion des stéréoisomères les moins stables vers les stéréoisomères les plus stables, qui, de manière surprenante, tout en étant réalisée sur le complexe intermédiaire hexaacide et non pas sur le complexe final, permet d'obtenir très majoritairement les isomères du complexe de formule (II) les plus stables. Le procédé selon l'invention a été défini dans les revendications. Bien que la description qui suit peut à titre d'information inclure de la matière allant au-delà de la portée de l'invention, cette portée et donc aussi l'étendue de protection restent limitées à l'objet défini par les revendications.The inventors have succeeded in developing a new process for preparing the complex of formula (II) making it possible to preferentially obtain the II-RRR and II-SSS diastereoisomers of said complex, which have particularly advantageous physicochemical properties. The process according to the invention comprises an isomeric enrichment step, by conversion of the least stable stereoisomers to the most stable stereoisomers, which, surprisingly, while being carried out on the intermediate hexaacid complex and not on the final complex , makes it possible to obtain the very majority of the most stable isomers of the complex of formula (II). The method according to the invention has been defined in the claims. Although the following description may for information include material going beyond the scope of the invention, this scope and therefore also the scope of protection remain limited to the subject matter defined by the claims.
La mise en œuvre d'un procédé qui permet d'obtenir majoritairement les diastéréoisomères d'intérêt est incontestablement avantageuse par rapport à l'alternative consistant à préparer le mélange de stéréoisomères, pour ensuite tenter de séparer les diastéréoisomères selon les techniques usuelles et ainsi isoler les stéréoisomères d'intérêt. En effet, outre le fait qu'il est plus aisé de mettre en œuvre un procédé dépourvu d'une étape de séparation de diastéréoisomères à l'échelle industrielle, l'absence de séparation permet d'une part un gain de temps considérable, et, d'autre part, d'améliorer le rendement global du procédé, en limitant autant que possible l'obtention des diastéréosiomères non désirés qui seraient in fine éliminés. Par ailleurs, les techniques de séparation usuelles impliquent de manière générale une utilisation abondante de solvants, qui, au-delà du coût financier, n'est pas souhaitable pour des raisons environnementales. De surcroît, la chromatographie sur silice en particulier est à éviter, compte tenu des risques pour la santé inhérents à une exposition professionnelle à la silice, classée comme cancérogène pour l'homme (groupe 1) par le Centre International de Recherche contre le Cancer.The implementation of a process which makes it possible to obtain mainly the diastereoisomers of interest is incontestably advantageous compared to the alternative consisting in preparing the mixture of stereoisomers, in order then to attempt to separate the diastereoisomers according to the usual techniques and thus isolate the stereoisomers of interest. Indeed, in addition to the fact that it is easier to implement a process devoid of a step for separating diastereoisomers on an industrial scale, the absence of separation allows on the one hand a considerable saving of time, and, on the other hand, to improve the overall yield of the process, by limiting as much as possible the obtaining of the undesired diastereoisomers which would ultimately be eliminated. Furthermore, the usual separation techniques generally involve an abundant use of solvents, which, beyond the financial cost, is not desirable for environmental reasons. In addition, chromatography on silica in particular should be avoided, given the health risks inherent in occupational exposure to silica, classified as carcinogenic for humans (group 1) by the International Agency for Research against Cancer.
Comme indiqué précédemment, le procédé de préparation du complexe de formule (II) mis au point par les inventeurs repose sur une étape d'enrichissement isomérique du complexe de gadolinium d'hexaacide intermédiaire de formule (I) représentée ci-après :
Le complexe de formule (I) correspond à plusieurs stéréoisomères, du fait de la présence des trois atomes de carbones asymétriques situés en position α sur les chaînes latérales du complexe, par rapport aux atomes d'azote du macrocycle sur lesquels sont greffées lesdites chaînes latérales. Ces trois carbones asymétriques sont marqués d'un astérisque (*) dans la formule (I) représentée ci-dessus.The complex of formula (I) corresponds to several stereoisomers, due to the presence of the three asymmetric carbon atoms located in the α position on the side chains of the complex, relative to the nitrogen atoms of the macrocycle on which the said side chains are grafted. . These three asymmetric carbons are marked with an asterisk (*) in formula (I) shown above.
Dans la mesure où chacun des 3 carbones asymétriques portant une fonction carboxylate peut être de configuration absolue R ou S, le complexe de formule (I) existe sous la forme de 8 stéréoisomères, dénommés ci-après I-RRR, I-SSS, I-RRS, I-SSR, I-RSS, I-SRR, I-RSR et I-SRS. Plus précisément, selon la nomenclature usuelle en stéréochimie, le complexe de formule (I) existe sous la forme de 4 paires d'énantiomères, diastéréoisomères entre elles.Insofar as each of the 3 asymmetric carbons carrying a carboxylate function can be of absolute configuration R or S, the complex of formula (I) exists in the form of 8 stereoisomers, referred to below as I-RRR, I-SSS, I -RRS, I-SSR, I-RSS, I-SRR, I-RSR and I-SRS. More precisely, according to the usual nomenclature in stereochemistry, the complex of formula (I) exists in the form of 4 pairs of enantiomers, diastereoisomers between them.
Les inventeurs sont parvenus à séparer et à identifier par chromatographie en phase liquide à haute performance (CLHP, plus communément désignée par l'acronyme anglais HPLC) et par chromatographie en phase liquide à ultra haute performance (CLUHP, plus communément désignée par l'acronyme anglais UHPLC) 4 massifs ou groupes d'isomères du complexe de formule (I) obtenu selon le procédé décrit dans le document
L'isoD cristallise dans l'eau. Des analyses par diffraction des rayons X ont permis aux inventeurs de déterminer la structure cristalline de ce groupe d'isomères, et ainsi de découvrir qu'il comprend les diastéréoisomères I-RRR et I-SSS du complexe de formule (I), de formules (I-RRR) et (I-SSS) représentées ci-après.
Il est à noter que les diastéréosiomères I-RRR et I-SSS du complexe de formule (I) sont énantiomères l'un de l'autre.It should be noted that the I-RRR and I-SSS diastereomers of the complex of formula (I) are enantiomers of each other.
L'étape d'enrichissement isomérique du procédé de l'invention vise à enrichir le complexe de gadolinium d'hexaacide intermédiaire de formule (I) en isoD.The isomeric enrichment step of the process of the invention aims to enrich the gadolinium complex with the intermediate hexaacid of formula (I) in isoD.
La synthèse du complexe de formule (II) implique notamment une conversion des fonctions acides carboxyliques du complexe hexaacide intermédiaire de formule (I) en fonction amide. Cette réaction d'amidification ne modifie pas la configuration absolue des trois atomes de carbones asymétriques du complexe de formule (I).The synthesis of the complex of formula (II) notably involves a conversion of the carboxylic acid functions of the intermediate hexaacid complex of formula (I) into an amide function. This amidation reaction does not modify the absolute configuration of the three asymmetric carbon atoms of the complex of formula (I).
Ainsi, lorsque la réaction d'amidification est réalisée sur le complexe hexaacide de formule (I) enrichi en isoD précédemment obtenu, elle permet d'obtenir le complexe de formule (II) enrichi en iso4.Thus, when the amidation reaction is carried out on the hexaacid complex of formula (I) enriched in isoD previously obtained, it makes it possible to obtain the complex of formula (II) enriched in iso4.
Le procédé selon l'invention implique donc le complexe de gadolinium d'hexaacide de formule (I) :
Par « excès diastéréoisomérique », on entend désigner, dans le cadre de la présente invention, et en ce qui concerne le complexe de gadolinium d'hexaacide de formule (I), le fait que ledit complexe est majoritairement présent sous la forme d'un isomère ou groupe d'isomères choisi(s) parmi les diastéréoisomères I-RRR, I-SSS, I-RRS, I-SSR, I-RSS, I-SRR, I-RSR et I-SRS. Ledit excès diastéréoisomérique est exprimé en pourcentage, et correspond à la quantité que représente l'isomère ou le groupe d'isomères majoritaire par rapport à la quantité totale du complexe de gadolinium d'hexaacide de formule (I). Il est entendu que ce pourcentage peut être aussi bien molaire que massique, dans la mesure où des isomères ont, par définition, la même masse molaire.The term "diastereoisomeric excess" is intended to denote, in the context of the present invention, and with regard to the complex of gadolinium of hexaacid of formula (I), the fact that said complex is mainly present in the form of an isomer or group of isomers chosen from among the diastereoisomers I-RRR, I-SSS, I-RRS, I-SSR, I-RSS, I-SRR, I-RSR and I-SRS. Said diastereoisomeric excess is expressed as a percentage, and corresponds to the quantity represented by the predominant isomer or group of isomers relative to the total quantity of the gadolinium complex of hexaacid of formula (I). It is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
Dans un mode de réalisation particulier du procédé selon l'invention, le complexe de formule (I) présente au moins 85 %, notamment au moins 90 %, en particulier au moins 95 %, de préférence au moins 97 %, avantageusement au moins 98 %, plus avantageusement au moins 99 % de l'excès diastéréoisomérique comprenant le mélange d'isomères I-RRR et I-SSS.In a particular embodiment of the process according to the invention, the complex of formula (I) has at least 85%, in particular at least 90%, in particular at least 95%, preferably at least 97%, advantageously at least 98 %, more preferably at least 99% of the diastereoisomeric excess comprising the mixture of I-RRR and I-SSS isomers.
De préférence, ledit excès diastéréoisomérique est constitué d'au moins 70 %, notamment d'au moins 80 %, avantageusement d'au moins 90 %, de préférence d'au moins 95 % du mélange d'isomères I-RRR et I-SSS.Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
Avantageusement, ledit excès diastéréoisomérique consiste en le mélange d'isomères I-RRR et I-SSS.Advantageously, said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
Le terme « mélange d'isomères I-RRR et I-SSS » recouvre également, par extension, le cas où seul l'un des isomères, qu'il s'agisse du I-RRR ou du I-SSS, est présent. Toutefois, le terme « mélange d'isomères I-RRR et I-SSS » désigne préférentiellement l'ensemble des cas où chacun des isomères I-RRR et I-SSS est présent en une quantité variable mais non nulle.The term “mixture of I-RRR and I-SSS isomers” also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present. However, the term “mixture of I-RRR and I-SSS isomers” preferably designates all the cases where each of the I-RRR and I-SSS isomers is present in a variable but non-zero amount.
Dans un mode de réalisation préféré du procédé selon l'invention, les isomères I-RRR et I-SSS sont présents au sein dudit mélange dans un rapport compris entre 65/35 et 35/65, notamment entre 60/40 et 40/60, en particulier entre 55/45 et 45/55. Avantageusement, le mélange de d'isomères I-RRR/I-SSS est un mélange racémique (50/50).In a preferred embodiment of the process according to the invention, the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60 , in particular between 55/45 and 45/55. Advantageously, the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
Plus particulièrement, l'excès diastéréoisomérique tel que défini précédemment correspond au pic 4 de la trace HPLC (c'est-à-dire le quatrième pic dans l'ordre d'élution et correspondant à isoD), caractérisé par un temps de rétention compris entre 33,9 et 37,5 minutes, typiquement d'environ 35,7 minutes, ladite trace étant obtenue en mettant en œuvre la méthode HPLC décrite ci-après.More particularly, the diastereoisomeric excess as defined previously corresponds to peak 4 of the HPLC trace (that is to say the fourth peak in the order of elution and corresponding to isoD), characterized by a retention time comprised between 33.9 and 37.5 minutes, typically about 35.7 minutes, said trace being obtained by implementing the HPLC method described below.
Par «trace HPLC», on entend, au sens de la présente invention, le profil des concentrations mesurées par le détecteur après passage et séparation d'un mélange de composés (en l'espèce d'isomères d'un composé) sur une phase stationnaire en fonction du temps pour une composition et un débit d'éluant donné. La trace HPLC est constituée de différents pics ou massifs caractéristiques du composé ou du mélange de composés analysés.By "HPLC trace" is meant, within the meaning of the present invention, the profile of the concentrations measured by the detector after passage and separation of a mixture of compounds (in this case isomers of a compound) on a phase stationary as a function of time for a given composition and eluent flow rate. The HPLC trace is made up of different peaks or peaks characteristic of the compound or mixture of compounds analyzed.
- colonne Symmetry® C18 - 250 x 4,6 mm - 5 µm de Waters.
Il s'agit d'une colonne HPLC en phase inverse à particules sphériques de silice avec un greffage C18 (octadécyl) et dont les silanols ont été traités par des agents de coiffage (end-capped). Elle est en outre caractérisée par une longueur de 250 mm, un diamètre intérieur de 4,6 mm, une granulométrie de 5 µm, une porosité de 100 Å et un taux de carbone de 19 %.
De manière préférentielle, la phase stationnaire utilisée doit être compatible avec les phases mobiles aqueuses.
- conditions d'analyse :
- gradient phase mobile (volumique) :
- Symmetry ® C18 column - 250 x 4.6 mm - 5 µm from Waters.
This is a reversed-phase HPLC column with spherical silica particles with C18 (octadecyl) grafting and whose silanols have been treated with capping agents (end-capped). It is also characterized by a length of 250 mm, an internal diameter of 4.6 mm, a grain size of 5 µm, a porosity of 100 Å and a carbon content of 19%.
Preferably, the stationary phase used must be compatible with the aqueous mobile phases.
- analysis conditions:
- mobile phase gradient (volume):
Le procédé selon l'invention permet d'obtenir le complexe de formule (II) :
Par « excès diastéréoisomérique », on entend désigner, dans le cadre de la présente invention, et en ce qui concerne le complexe de formule (II), le fait que ledit complexe est majoritairement présent sous la forme d'un isomère ou groupe d'isomères choisi(s) parmi les diastéréoisomères II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR et II-SRS. Ledit excès diastéréoisomérique est exprimé en pourcentage et correspond à la quantité que représente l'isomère ou le groupe d'isomères majoritaire par rapport à la quantité totale du complexe de formule (II). Il est entendu que ce pourcentage peut être aussi bien molaire que massique, dans la mesure où des isomères ont, par définition, la même masse molaire.By "diastereoisomeric excess" is meant, in the context of the present invention, and with regard to the complex of formula (II), the fact that said complex is mainly present in the form of an isomer or group of isomers chosen from among diastereoisomers II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS. Said diastereoisomeric excess is expressed as a percentage and corresponds to the quantity represented by the predominant isomer or group of isomers relative to the total quantity of the complex of formula (II). It is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
Dans un mode de réalisation particulier, le complexe de formule (II) obtenu par le procédé selon l'invention présente au moins 85 %, notamment au moins 90 %, en particulier au moins 92 %, de préférence au moins 94 %, avantageusement au moins 97 %, plus avantageusement au moins 99 % de l'excès diastéréoisomérique comprenant le mélange d'isomères II-RRR et II-SSS.In a particular embodiment, the complex of formula (II) obtained by the process according to the invention has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94%, advantageously at least at least 97%, more preferably at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
De préférence, ledit excès diastéréoisomérique est constitué d'au moins 70 %, notamment d'au moins 80 %, avantageusement d'au moins 90 %, de préférence d'au moins 95 % du mélange d'isomères II-RRR et II-SSS.Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
Avantageusement, ledit excès diastéréoisomérique consiste en le mélange d'isomères II-RRR et II-SSS.Advantageously, said diastereoisomeric excess consists of the mixture of II-RRR and II-SSS isomers.
Le terme « mélange d'isomères II-RRR et II-SSS » recouvre également, par extension, le cas où seul l'un des isomères, qu'il s'agisse du II-RRR ou du II-SSS, est présent. Toutefois, le terme « mélange d'isomères II-RRR et II-SSS » désigne préférentiellement l'ensemble des cas où chacun des isomères II-RRR et II-SSS est présent en une quantité variable mais non nulle.The term “mixture of II-RRR and II-SSS isomers” also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present. However, the term "mixture of II-RRR and II-SSS isomers" preferably designates the whole cases where each of the II-RRR and II-SSS isomers is present in a variable but non-zero amount.
Dans un mode de réalisation préféré du procédé selon l'invention, les isomères II-RRR et II-SSS sont présents au sein dudit mélange dans un rapport compris entre 65/35 et 35/65, notamment entre 60/40 et 40/60, en particulier entre 55/45 et 45/55. Avantageusement, les isomères II-RRR et II-SSS sont présents au sein du mélange dans un rapport 50/50.In a preferred embodiment of the process according to the invention, the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60 , in particular between 55/45 and 45/55. Advantageously, the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
Plus particulièrement, l'excès diastéréoisomérique tel que défini précédemment correspond au pic 4 de la trace UHPLC (c'est-à-dire le quatrième massif d'isomères dans l'ordre d'élution et correspondant à iso4), caractérisé par un temps de rétention compris entre 6,0 et 6,6 minutes, typiquement d'environ 6,3 minutes, ladite trace étant obtenue en mettant en œuvre la méthode UHPLC décrite ci-après.More particularly, the diastereoisomeric excess as defined above corresponds to peak 4 of the UHPLC trace (i.e. the fourth mass of isomers in the order of elution and corresponding to iso4), characterized by a time retention of between 6.0 and 6.6 minutes, typically about 6.3 minutes, said trace being obtained by implementing the UHPLC method described below.
Par « trace UHPLC », on entend, au sens de la présente invention, le profil des concentrations mesurées par le détecteur après passage et séparation d'un mélange de composés (en l'espèce d'isomères d'un composé) sur une phase stationnaire en fonction du temps pour une composition et un débit d'éluant donné. La trace UHPLC est constituée de différents pics ou massifs caractéristiques du composé ou du mélange de composés analysés.By "UHPLC trace" is meant, within the meaning of the present invention, the profile of the concentrations measured by the detector after passage and separation of a mixture of compounds (in this case isomers of a compound) on a phase stationary as a function of time for a given composition and eluent flow rate. The UHPLC trace consists of different peaks or peaks characteristic of the compound or mixture of compounds analyzed.
- colonne CORTECS® UPLC T3 150 x 2,1 mm - 1,6 µm de Waters.CORTECS ® UPLC T3 column 150 x 2.1 mm - 1.6 µm from Waters.
Il s'agit d'une colonne UPLC en phase inverse à particules sphériques constituées d'un noyau, préférentiellement très dur, en silice entouré d'une silice poreuse avec un greffage C18 (octadécyl) trifonctionnel, et dont les silanols ont été traités par des agents de coiffage (end-capped). Elle est en outre caractérisée par une longueur de 150 mm, un diamètre intérieur de 2,1 mm, une granulométrie de 1,6 µm, une porosité de 120 Å et un taux de carbone de 4,7 %.This is a reverse phase UPLC column with spherical particles consisting of a core, preferably very hard, in silica surrounded by a porous silica with a trifunctional C18 (octadecyl) grafting, and whose silanols have been treated with styling agents (end-capped). It is also characterized by a length of 150 mm, an internal diameter of 2.1 mm, a grain size of 1.6 µm, a porosity of 120 Å and a carbon content of 4.7%.
De manière préférentielle, la phase stationnaire utilisée doit être compatible avec les phases mobiles aqueuses.
- conditions d'analyse :
- gradient phase mobile (% v /v) :
- analysis conditions:
- mobile phase gradient (% v /v):
Dans le procédé selon l'invention, le complexe de formule (II) est obtenu par amidification à partir du complexe de formule (I) tel que défini ci-dessus et du 3-amino-1,2-propanediol, sous forme racémique ou énantiomériquement pure, de préférence sous forme racémique.In the process according to the invention, the complex of formula (II) is obtained by amidation from the complex of formula (I) as defined above and 3-amino-1,2-propanediol, in racemic form or enantiomerically pure, preferably in racemic form.
Par « amidification », on entend, au sens de la présente invention, la réaction de conversion d'une fonction acide carboxylique en fonction amide par réaction avec une fonction amine.By “amidification” is meant, within the meaning of the present invention, the conversion reaction of a carboxylic acid function into an amide function by reaction with an amine function.
Une telle réaction peut notamment être réalisée après activation des fonctions acides carboxyliques, comme cela est détaillé dans la suite de la description.Such a reaction can in particular be carried out after activation of the carboxylic acid functions, as is detailed in the remainder of the description.
La présente invention concerne donc un procédé de préparation du complexe de formule (II) comprenant les étapes successives suivantes :
- a) Complexation de l'hexaacide de formule (III) suivante
- b) Isomérisation par chauffage du complexe de gadolinium d'hexaacide de formule (I) dans une solution aqueuse à pH compris
entre 2et 4, pour obtenir un complexe diastéréoisomériquement enrichi constitué d'au moins 80 % d'un excès diastéréoisomérique comprenant un mélange des isomères I-RRR et I-SSS dudit complexe de gadolinium d'hexaacide de formule (I), et - c) Formation, à partir du complexe diastéréoisomériquement enrichi obtenu à l'étape b), du complexe de formule (II), par réaction avec le 3-amino-1,2-propanediol.
- a) Complexation of the following hexaacid of formula (III)
- b) Isomerization by heating of the hexaacid gadolinium complex of formula (I) in an aqueous solution at a pH of between 2 and 4, to obtain a diastereoisomerically enriched complex consisting of at least 80% of a diastereoisomeric excess comprising a mixture I-RRR and I-SSS isomers of said hexaacid gadolinium complex of formula (I), and
- c) Formation, from the diastereoisomerically enriched complex obtained in step b), of the complex of formula (II), by reaction with 3-amino-1,2-propanediol.
Dans la présente description, sauf mention contraire, on utilise indifféremment les expressions « Gd », « gadolinium » et « Gd3+ » pour désigner l'ion Gd3+. Par extension, il peut également s'agir d'une source de gadolinium libre, tels que le chlorure de gadolinium (GdCl3) ou l'oxyde de gadolinium (Gd2O3).In the present description, unless otherwise stated, the expressions “Gd”, “gadolinium” and “Gd 3+ ” are used interchangeably to designate the Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide (Gd 2 O 3 ).
Dans la présente invention, on désigne par « Gd libre » les formes non complexées du gadolinium, et de préférence disponibles pour une complexation. Il s'agit typiquement de l'ion Gd3+ solubilisé dans l'eau. Par extension, il peut également s'agir d'une source de gadolinium libre, tels que le chlorure de gadolinium (GdCl3) ou l'oxyde de gadolinium.In the present invention, the term “free Gd” denotes the uncomplexed forms of gadolinium, and preferably available for complexation. This is typically the water-solubilized Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide.
Au cours de cette étape a lieu une réaction de complexation entre l'hexaacide de formule (III) et le gadolinium, qui permet d'obtenir le complexe de gadolinium d'hexaacide de formule (I) telle que définie précédemment.During this step, a complexation reaction takes place between the hexaacid of formula (III) and gadolinium, which makes it possible to obtain the gadolinium complex of hexaacid of formula (I) as defined above.
Selon un mode de réalisation particulier, l'étape a) comprend la réaction entre l'hexaacide de formule (III) et une source de Gd libre dans de l'eau.According to a particular embodiment, step a) comprises the reaction between the hexaacid of formula (III) and a source of free Gd in water.
Dans un mode de réalisation préféré, la source de Gd libre est du GdCl3 ou du Gd2O3, de préférence du Gd2O3.In a preferred embodiment, the source of free Gd is GdCl 3 or Gd 2 O 3 , preferably Gd 2 O 3 .
De préférence, les réactifs utilisés à l'étape a), c'est-à-dire la source de gadolinium (typiquement l'oxyde de gadolinium), l'hexaacide de formule (III) et l'eau, sont les plus purs possibles, notamment en ce qui concerne les impuretés métalliques.Preferably, the reagents used in step a), that is to say the source of gadolinium (typically gadolinium oxide), the hexaacid of formula (III) and water, are the purest. possible, especially with regard to metallic impurities.
Ainsi, la source de gadolinium sera avantageusement l'oxyde de gadolinium, de préférence avec une pureté supérieure à 99,99 %, et de manière encore préférée supérieure à 99,999 %.Thus, the source of gadolinium will advantageously be gadolinium oxide, preferably with a purity greater than 99.99%, and even more preferably greater than 99.999%.
L'eau utilisée dans le procédé comprend de préférence moins de 50 ppm de calcium, de manière encore préférée moins de 20 ppm, et de manière préférée entre toutes moins de 15 ppm de calcium. Généralement, l'eau employée dans le procédé est de l'eau désionisée, de l'eau pour injection (eau ppi) ou de l'eau purifiée.The water used in the process preferably comprises less than 50 ppm calcium, more preferably less than 20 ppm, and most preferably less than 15 ppm calcium. Generally, the water used in the process is deionized water, water for injection (water for injection) or purified water.
Avantageusement, les quantités des réactifs (l'hexaacide de formule (III) et le gadolinium) utilisées lors de cette étape a) correspondent aux, ou sont proches des, proportions stœchiométriques, telles que dictées par l'équation-bilan de la réaction de complexation ayant lieu au cours de cette étape.Advantageously, the quantities of the reagents (the hexaacid of formula (III) and the gadolinium) used during this stage a) correspond to, or are close to, stoichiometric proportions, as dictated by the equation-balance of the reaction of complexation taking place during this step.
Par « proche des proportions stœchiométriques », on entend signifier que l'écart entre les proportions molaires dans lesquelles sont introduits les réactifs et les proportions stœchiométriques est inférieur à 15 %, notamment inférieur à 10 %, de préférence inférieur à 8 %.By “close to stoichiometric proportions”, is meant that the difference between the molar proportions in which the reactants are introduced and the stoichiometric proportions is less than 15%, in particular less than 10%, preferably less than 8%.
Le gadolinium peut notamment être introduit en léger excès par rapport aux proportions stœchiométriques. Le rapport de la quantité de matière introduite en gadolinium sur la quantité de matière introduite en hexaacide de formule (III) est alors supérieur à 1, mais typiquement inférieur à 1,15, notamment inférieur à 1,10, avantageusement inférieur à 1,08. Autrement dit, la quantité de gadolinium introduite est supérieure à 1 équivalent (éq.), mais typiquement inférieure à 1,15 éq., notamment inférieure à 1,10 éq., avantageusement inférieure à 1,08 éq., par rapport à la quantité d'hexaacide de formule (III) introduite, qui correspond quant à elle à 1 équivalent. Dans le mode de réalisation préféré selon lequel la source de gadolinium libre est Gd2O3, la quantité de Gd2O3 introduite est alors typiquement supérieure à 0,5 éq., mais inférieure à 0,575 éq., notamment inférieure à 0,55 éq., avantageusement inférieure à 0,54 éq., par rapport à la quantité d'hexaacide de formule (III) introduite (1 éq.).The gadolinium can in particular be introduced in a slight excess with respect to the stoichiometric proportions. The ratio of the amount of material introduced in gadolinium to the amount of material introduced in hexaacid of formula (III) is then greater than 1, but typically less than 1.15, in particular less than 1.10, advantageously less than 1.08 . In other words, the amount of gadolinium introduced is greater than 1 equivalent (eq.), but typically less than 1.15 eq., in particular less than 1.10 eq., advantageously less than 1.08 eq., relative to the amount of hexaacid of formula (III) introduced, which for its part corresponds to 1 equivalent. In the preferred embodiment according to which the source of free gadolinium is Gd 2 O 3 , the quantity of Gd 2 O 3 introduced is then typically greater than 0.5 eq., but less than 0.575 eq., in particular less than 0, 55 eq., advantageously less than 0.54 eq., relative to the quantity of hexaacid of formula (III) introduced (1 eq.).
Selon un mode de réalisation particulier, l'étape a) comprend les étapes successives suivantes :
- a1) Préparation d'une solution aqueuse d'hexaacide de formule (III), et
- a2) Ajout, à la solution aqueuse obtenue à l'étape a1), d'une source de gadolinium libre.
- a1) Preparation of an aqueous solution of hexaacid of formula (III), and
- a2) Addition, to the aqueous solution obtained in step a1), of a source of free gadolinium.
Dans ce mode de réalisation, la teneur en hexaacide de formule (III) dans la solution aqueuse préparée lors de l'étape a1) est typiquement comprise entre 10% et 60%, notamment entre 15 % et 45 %, de préférence entre 20 % et 35 %, avantageusement entre 25 % et 35 %, de manière encore plus avantageuse entre 25 % et 30 % en poids par rapport au poids total de la solution aqueuse.In this embodiment, the content of hexaacid of formula (III) in the aqueous solution prepared during step a1) is typically between 10% and 60%, in particular between 15% and 45%, preferably between 20% and 35%, advantageously between 25% and 35%, even more advantageously between 25% and 30% by weight relative to the total weight of the aqueous solution.
De manière préférentielle, les étapes a) et b) sont effectuées selon un mode de réalisation monotope (ou « one-pot » en anglais), c'est-à-dire dans le même réacteur et sans étape intermédiaire d'isolement ou de purification.Preferably, steps a) and b) are carried out according to a one-pot embodiment, that is to say in the same reactor and without an intermediate step of isolation or purification.
Ainsi, dans ce mode de réalisation préféré, le complexe de gadolinium d'hexaacide de formule (I) formé au cours de l'étape a) est directement soumis à l'étape b) d'isomérisation, sans être isolé ou purifié, et dans le même réacteur que celui utilisé pour l'étape a).Thus, in this preferred embodiment, the hexaacid gadolinium complex of formula (I) formed during step a) is directly subjected to step b) of isomerization, without being isolated or purified, and in the same reactor as that used for step a).
Le complexe de gadolinium d'hexaacide de formule (I) formé par la réaction de complexation entre l'hexaacide de formule (III) et le gadolinium au cours de l'étape a) est initialement obtenu sous la forme d'un mélange de diastéréoisomères.The gadolinium complex of hexaacid of formula (I) formed by the complexation reaction between the hexaacid of formula (III) and gadolinium during step a) is initially obtained in the form of a mixture of diastereoisomers .
L'étape b) vise à enrichir le mélange de diastéréoisomères en les isomères I-RRR et I-SSS, pour obtenir le complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi constitué d'au moins 85 %, notamment d'au moins 90 %, en particulier d'au moins 95 %, de préférence d'au moins 97 %, avantageusement d'au moins 98 %, plus avantageusement d'au moins 99 % de l'excès diastéréoisomérique comprenant le mélange des isomères I-RRR et I-SSS.Step b) aims to enrich the mixture of diastereoisomers in the I-RRR and I-SSS isomers, to obtain the complex of gadolinium of hexaacid of formula (I) diastereoisomerically enriched consisting of at least 85%, in particular of at least 90%, in particular at least 95%, preferably at least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of isomers I -RRR and I-SSS.
De préférence, ledit excès diastéréoisomérique est constitué d'au moins 70 %, notamment d'au moins 80 %, avantageusement d'au moins 90 %, de préférence d'au moins 95 % du mélange d'isomères I-RRR et I-SSS.Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
Avantageusement, ledit excès diastéréoisomérique consiste en le mélange d'isomères I-RRR et I-SSS.Advantageously, said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
Les inventeurs ont en effet découvert que des facteurs tels que le pH et la température de la solution de complexe de gadolinium d'hexaacide de formule (I) obtenue à l'issue de l'étape a) ont une influence sur le rapport dans lequel les différents isomères du complexe de formule (I) sont présents au sein du mélange de diastéréoisomères. Au cours du temps, le mélange tend à s'enrichir en un groupe d'isomères comprenant les isomères qui sont, de façon étonnante, les plus stables thermodynamiquement mais aussi chimiquement, en l'espèce les isomères I-RRR et I-SSS.The inventors have in fact discovered that factors such as the pH and the temperature of the solution of gadolinium complex of hexaacid of formula (I) obtained at the end of step a) have an influence on the ratio in which the various isomers of the complex of formula (I) are present within the mixture of diastereoisomers. Over time, the mixture tends to be enriched in a group of isomers comprising the isomers which are, surprisingly, the most stable thermodynamically but also chemically, in this case the I-RRR and I-SSS isomers.
Le terme « mélange d'isomères I-RRR et I-SSS » recouvre également, par extension, le cas où seul l'un des isomères, qu'il s'agisse du I-RRR ou du I-SSS, est présent. Toutefois, le terme « mélange d'isomères I-RRR et I-SSS » désigne préférentiellement l'ensemble des cas où chacun des isomères I-RRR et I-SSS est présent en une quantité variable mais non nulle.The term “mixture of I-RRR and I-SSS isomers” also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present. However, the term “mixture of I-RRR and I-SSS isomers” preferably designates all the cases where each of the I-RRR and I-SSS isomers is present in a variable but non-zero amount.
Dans un mode de réalisation préféré, les isomères I-RRR et I-SSS sont présents au sein dudit mélange dans un rapport compris entre 65/35 et 35/65, notamment entre 60/40 et 40/60, en particulier entre 55/45 et 45/55. Avantageusement, le mélange de d'isomères I-RRR/I-SSS est un mélange racémique (50/50).In a preferred embodiment, the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/ 45 and 45/55. Advantageously, the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
L'étape b) d'isomérisation du complexe de gadolinium d'hexaacide de formule (I) dans une solution aqueuse est typiquement conduite à un pH compris entre 2 et 4, notamment entre 2 et 3, avantageusement entre 2,2 et 2,8.Step b) of isomerization of the hexaacid gadolinium complex of formula (I) in an aqueous solution is typically carried out at a pH of between 2 and 4, in particular between 2 and 3, advantageously between 2.2 and 2, 8.
Le pH est préférentiellement ajusté avec un acide, de préférence un acide inorganique, tel que l'acide chlorhydrique, l'acide bromhydrique, l'acide sulfurique, l'acide nitrique ou l'acide phosphorique, par exemple avec de l'acide chlorhydrique.The pH is preferably adjusted with an acid, preferably an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, for example with hydrochloric acid .
Il est tout à fait surprenant que dans de telles conditions de pH, un enrichissement du mélange en des isomères particuliers, en l'espèce les isomères I-RRR et I-SSS, se produise, dans la mesure où il est connu dans l'art que les chélates de gadolinium sont caractérisés par une faible inertie cinétique en milieu acide. En effet, plus la concentration en ions H+ est élevée dans le milieu, plus la probabilité qu'un proton soit transféré sur l'un des atomes donneurs du ligand est forte, entrainant ainsi la dissociation du complexe. Par conséquent, l'homme du métier se serait attendu à ce que le fait de placer le complexe de gadolinium d'hexaacide de formule (I) en une solution aqueuse à un pH compris entre 2 et 4 entraîne la dissociation dudit complexe, et non pas son isomérisation en I-RRR et I-SSS.It is quite surprising that under such pH conditions, an enrichment of the mixture in particular isomers, in this case the I-RRR and I-SSS isomers, occurs, insofar as it is known in the art that gadolinium chelates are characterized by low kinetic inertia in an acid medium. Indeed, the higher the concentration of H + ions in the medium, the greater the probability that a proton will be transferred to one of the donor atoms of the ligand, thus causing the dissociation of the complex. Consequently, a person skilled in the art would have expected that placing the hexaacid gadolinium complex of formula (I) in an aqueous solution at a pH of between 2 and 4 would lead to the dissociation of said complex, and not not its isomerization to I-RRR and I-SSS.
Il est à noter que la gamme de pH recommandée par le document
L'étape b) est réalisée typiquement à une température comprise entre 80°C et 130°C, notamment entre 90°C et 125°C, de préférence entre 98°C et 122°C, avantageusement entre 100°C et 120°C, typiquement pendant une durée comprise entre 10h et 72h, notamment entre 10h et 60h, avantageusement entre 12h et 48h.Step b) is typically carried out at a temperature between 80°C and 130°C, in particular between 90°C and 125°C, preferably between 98°C and 122°C, advantageously between 100°C and 120°C. C, typically for a period of between 10h and 72h, in particular between 10h and 60h, advantageously between 12h and 48h.
Contre toute attente, de telles conditions de température, qui, cumulées aux conditions de pH susmentionnées, devraient favoriser l'instabilité du chélate de gadolinium, n'aboutissent pas à sa décomplexation ou à la formation de toute autre impureté, mais à son isomérisation en I-RRR et I-SSS.Against all expectation, such temperature conditions, which, combined with the aforementioned pH conditions, should favor the instability of the gadolinium chelate, do not lead to its decomplexation or to the formation of any other impurity, but to its isomerization in I-RRR and I-SSS.
Dans un mode de réalisation particulier, la solution aqueuse de l'étape b) comprend de l'acide acétique. L'étape b) est alors avantageusement réalisée à une température comprise entre 100°C et 120°C, notamment entre 110°C et 118°C, typiquement pendant une durée comprise entre 12h et 48h, notamment entre 20h et 30h, en particulier entre 24h et 26h.In a particular embodiment, the aqueous solution of step b) comprises acetic acid. Step b) is then advantageously carried out at a temperature of between 100°C and 120°C, in particular between 110°C and 118°C, typically for a period of between 12 h and 48 h, in particular between 20 h and 30 h, in particular between 24h and 26h.
L'acide acétique est de préférence ajouté avant le chauffage de la solution de complexe de gadolinium d'hexaacide de formule (I) obtenue lors de l'étape a) dans une quantité telle que la teneur en acide acétique est comprise entre 25 % et 75 %, notamment entre 40 % et 50 % en masse par rapport à la masse d'hexaacide de formule (III) utilisée lors de l'étape a).The acetic acid is preferably added before heating the solution of gadolinium hexaacid complex of formula (I) obtained during step a) in an amount such that the acetic acid content is between 25% and 75%, in particular between 40% and 50% by mass relative to the mass of hexaacid of formula (III) used during step a).
Lorsque la solution aqueuse est chauffée à une température avantageusement comprise entre 100°C et 120°C, typiquement entre 110°C et 118°C, de l'acide acétique est ajouté au fur et à mesure que l'eau s'évapore, de façon à maintenir un volume de solution constant.When the aqueous solution is heated to a temperature advantageously between 100°C and 120°C, typically between 110°C and 118°C, acetic acid is added as the water evaporates, so as to maintain a constant volume of solution.
Selon un mode de réalisation préféré, à l'issue de l'étape b), le complexe diastéréoisomériquement enrichi est isolé par cristallisation, de préférence par cristallisation par ensemencement.According to a preferred embodiment, at the end of step b), the diastereoisomerically enriched complex is isolated by crystallization, preferably by crystallization by seeding.
Dans ce mode de réalisation, l'étape b) comprend les étapes successives suivantes :
- b1) Isomérisation par chauffage du complexe de gadolinium d'hexaacide de formule (I) dans une solution aqueuse à pH compris
entre 2et 4, pour obtenir un complexe diastéréoisomériquement enrichi constitué d'au moins 80% de l'excès diastéréoisomérique comprenant le mélange des isomères I-RRR et I-SSS dudit complexe de gadolinium d'hexaacide de formule (I), et - b2) Isolement par cristallisation dudit complexe diastéréoisomériquement enrichi de préférence par cristallisation par ensemencement.
- b1) Isomerization by heating of the hexaacid gadolinium complex of formula (I) in an aqueous solution at pH between 2 and 4, to obtain a diastereoisomerically enriched complex consisting of at least 80% of the diastereoisomeric excess comprising the mixture I-RRR and I-SSS isomers of said hexaacid gadolinium complex of formula (I), and
- b2) Isolation by crystallization of said diastereoisomerically enriched complex, preferably by crystallization by seeding.
L'étape b2) de cristallisation vise d'une part à éliminer les impuretés éventuellement présentes dans la solution aqueuse, qui peuvent résulter d'étapes antérieures, de façon à obtenir un produit de plus grande pureté, décoloré, sous forme de cristaux, et d'autre part à poursuivre l'enrichissement diastéréoisomérique du complexe de gadolinium d'hexaacide de formule (I), de façon à obtenir un excès diastéréoisomérique comprenant le mélange des isomères I-RRR et I-SSS dudit complexe supérieur à celui obtenu à l'issue de l'étape b1).Step b2) of crystallization aims on the one hand to eliminate any impurities present in the aqueous solution, which may result from previous steps, so as to obtain a product of greater purity, discolored, in the form of crystals, and on the other hand to continue the diastereoisomeric enrichment of the gadolinium complex of hexaacid of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said complex greater than that obtained at the result of step b1).
En effet, les isomères I-RRR et I-SSS du complexe hexaacide de formule (I) cristallisent dans l'eau. En revanche, le complexe de gadolinium d'hexaacide de formule (I) non enrichi en lesdits isomères ne cristallise pas.Indeed, the I-RRR and I-SSS isomers of the hexaacid complex of formula (I) crystallize in water. On the other hand, the hexaacid gadolinium complex of formula (I) not enriched in said isomers does not crystallize.
Le fait que les isomères I-RRR et I-SSS, en lesquels le complexe tend à s'enrichir au cours de l'étape b) (et ce contre toute attente, au vu des conditions dans lesquelles elle est réalisée), sont les seuls isomères du complexe à cristalliser dans l'eau constitue un résultat tout à fait inattendu. L'isomérisation et la cristallisation contribuent ainsi de manière synergique à l'enrichissement en isomères I-RRR et I-SSS, et dès lors à l'efficacité globale du procédé selon l'invention.The fact that the I-RRR and I-SSS isomers, in which the complex tends to become enriched during step b) (and this against all expectation, given the conditions under which it is carried out), are the only isomers of the complex to crystallize in water constitutes a completely unexpected result. Isomerization and crystallization thus contribute synergistically to the enrichment in I-RRR and I-SSS isomers, and therefore to the overall efficiency of the process according to the invention.
Par ailleurs, il est à noter que la cristallisation dans l'eau des isomères d'intérêt du complexe de gadolinium d'hexaacide de formule (I) permet d'éviter un ajout de solvant tel que décrit dans l'exemple 7 du document
L'étape b2) est réalisée avantageusement à une température comprise entre 10°C et 70°C, notamment entre 30°C et 65°C, en particulier entre 35° et 60°C.Stage b2) is advantageously carried out at a temperature of between 10°C and 70°C, in particular between 30°C and 65°C, in particular between 35° and 60°C.
Selon une variante, après abaissement de la température de la solution aqueuse, de façon à ce que celle-ci soit comprise dans les gammes indiquées ci-dessus, le processus de cristallisation est induit par ensemencement. La « cristallisation par ensemencement », aussi appelée « cristallisation par amorçage », comprend l'introduction dans le réacteur dans lequel la cristallisation est effectuée (aussi appelé cristallisoir) d'une quantité connue de cristaux, appelée « semence » ou « amorce ». Cela permet de diminuer le temps de cristallisation. La cristallisation par ensemencement est bien connue de l'homme du métier.According to a variant, after lowering the temperature of the aqueous solution, so that the latter is within the ranges indicated above, the crystallization process is induced by seeding. "Crystallization by seed", also called "crystallization by seed", includes the introduction into the reactor in which the crystallization is carried out (also called crystallizer) of a known quantity of crystals, called "seed" or "starter". This reduces the crystallization time. Seed crystallization is well known to those skilled in the art.
Dans le procédé selon l'invention, l'ensemencement par utilisation d'une amorce, en l'espèce des cristaux de complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi ajoutés dans la solution aqueuse du complexe diastéréoisomériquement enrichi dont la température a été préalablement abaissée, permet d'obtenir une nucléation, et ainsi d'initier la cristallisation. La durée de la cristallisation par ensemencement est avantageusement comprise entre 2h et 20h, de préférence entre 6h et 18h, typiquement, elle est de 16h.In the process according to the invention, the seeding by use of a primer, in this case crystals of gadolinium complex of diastereoisomerically enriched hexaacid of formula (I) added to the aqueous solution of the diastereoisomerically enriched complex whose temperature has been previously lowered, makes it possible to obtain nucleation, and thus to initiate crystallization. The duration of the crystallization by seeding is advantageously between 2 h and 20 h, preferably between 6 h and 18 h, typically, it is 16 h.
Les cristaux de complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi sont alors isolés typiquement par filtration et séchage, en mettant en œuvre toute technique bien connue de l'homme de l'art.The crystals of diastereoisomerically enriched hexaacid gadolinium complex of formula (I) are then typically isolated by filtration and drying, using any technique well known to those skilled in the art.
Avantageusement, le degré de pureté du complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi isolé à l'issue de l'étape b2) est supérieur à 95 %, notamment supérieur à 98 %, avantageusement supérieur à 99 %, ledit degré de pureté étant exprimé en pourcentage massique du complexe de formule (I) par rapport à la masse totale obtenue à l'issue de l'étape b2).Advantageously, the degree of purity of the diastereoisomerically enriched gadolinium hexaacid complex of formula (I) isolated at the end of step b2) is greater than 95%, in particular greater than 98%, advantageously greater than 99%, said degree of purity being expressed as a mass percentage of the complex of formula (I) relative to the total mass obtained at the end of step b2).
Dans un mode de réalisation particulier, le complexe diastéréoisomériquement enrichi de l'étape b) isolé par cristallisation est à nouveau purifié par recristallisation, pour obtenir un complexe diastéréoisomériquement enrichi et purifié.In a particular embodiment, the diastereoisomerically enriched complex of step b) isolated by crystallization is again purified by recrystallization, to obtain a diastereoisomerically enriched and purified complex.
Dans ce mode de réalisation, l'étape b) comprend, outre les étapes successives b1) et b2) précédemment décrites, une étape b3) de purification par recristallisation du complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi isolé.In this embodiment, step b) comprises, in addition to the successive steps b1) and b2) previously described, a step b3) of purification by recrystallization of the isolated diastereoisomerically enriched gadolinium hexaacid complex of formula (I).
L'étape b3) de recristallisation vise, à l'instar de l'étape b2) de cristallisation, d'une part, à obtenir un produit de plus grande pureté, et, d'autre part, à poursuivre l'enrichissement diastéréoisomérique du complexe de gadolinium d'hexaacide de formule (I), de façon à obtenir un excès diastéréoisomérique comprenant le mélange des isomères I-RRR et I-SSS dudit complexe supérieur à celui obtenu à l'issue de l'étape b2).Step b3) of recrystallization aims, like step b2) of crystallization, on the one hand, to obtain a product of greater purity, and, on the other hand, to continue the diastereoisomeric enrichment of the hexaacid gadolinium complex of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said complex greater than that obtained at the end of step b2).
L'étape b3) comprend typiquement les sous-étapes successives suivantes :
- mise en suspension du complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi isolé lors de l'étape b2) en solution aqueuse, de préférence dans de l'eau,
- solubilisation dudit complexe par chauffage à une température avantageusement comprise entre 80°C et 120°C, par exemple à 100°C,
- recristallisation, de préférence par ensemencement, à une température avantageusement comprise entre 10°C et 90°C, notamment entre 20°C et 87°C, en particulier entre 55°C et 85°C, typiquement pendant une durée comprise entre 2h et 20h, notamment entre 6h et 18h, et
- isolement des cristaux de complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi et purifié, par exemple par filtration et séchage.
- suspending the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) isolated during step b2) in aqueous solution, preferably in water,
- solubilization of said complex by heating to a temperature advantageously between 80° C. and 120° C., for example at 100° C.,
- recrystallization, preferably by seeding, at a temperature advantageously between 10°C and 90°C, in particular between 20°C and 87°C, in particular between 55°C and 85°C, typically for a period of between 2 hours and 8 p.m., in particular between 6 a.m. and 6 p.m., and
- isolation of the crystals of gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched and purified, for example by filtration and drying.
Le degré de pureté du complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi purifié isolé à l'issue de l'étape b3) est typiquement supérieur à 98 %, notamment supérieur à 99 %, avantageusement supérieur à 99,5 %, ledit degré de pureté étant exprimé en pourcentage massique du complexe de formule (I) par rapport à la masse totale obtenue à l'issue de l'étape b2).The degree of purity of the purified diastereoisomerically enriched gadolinium hexaacid complex of formula (I) isolated at the end of step b3) is typically greater than 98%, in particular greater than 99%, advantageously greater than 99.5% , said degree of purity being expressed as a mass percentage of the complex of formula (I) relative to the total mass obtained at the end of step b2).
Dans un autre mode de réalisation, le complexe diastéréoisomériquement enrichi de l'étape b) est encore enrichi par décomplexation sélective des diastéréoisomères du complexe de formule (I) autres que les diastéréoisomères I-RRR et I-SSS, i.e. par décomplexation sélective des diastéréoisomères I-RSS, I-SRR, I-RSR, I-SRS, I-RRS et I-SSR.In another embodiment, the diastereoisomerically enriched complex of step b) is further enriched by selective decomplexation of the diastereoisomers of the complex of formula (I) other than the I-RRR and I-SSS diastereoisomers, i.e. by selective decomplexation of the diastereoisomers I-RSS, I-SRR, I-RSR, I-SRS, I-RRS and I-SSR.
Dans ce mode de réalisation, l'étape b) comprend, outre les étapes successives b1) et b2) précédemment décrites, une étape b4) de décomplexation sélective des diastéréoisomères du complexe de formule (I) autres que les diastéréoisomères I-RRR et I-SSS. Dans cette variante, l'étape b) peut en outre comprendre l'étape b3) précédemment décrite, ladite étape b3) étant mise en œuvre entre les étapes b2) et b4), ou après l'étape b4).In this embodiment, step b) comprises, in addition to the successive steps b1) and b2) previously described, a step b4) of selective decomplexation of the diastereoisomers of the complex of formula (I) other than the diastereoisomers I-RRR and I -SSS. In this variant, step b) can also comprise step b3) previously described, said step b3) being implemented between steps b2) and b4), or after step b4).
L'étape b4) de décomplexation sélective vise à poursuivre l'enrichissement diastéréoisomérique du complexe de gadolinium d'hexaacide de formule (I), de façon à obtenir un excès diastéréoisomérique comprenant le mélange des isomères I-RRR et I-SSS dudit complexe supérieur à celui obtenu à l'issue de l'étape b2) ou à l'issue de l'étape b3), lorsque celle-ci est mise en œuvre préalablement à l'étape b4).Step b4) of selective decomplexation aims to continue the diastereoisomeric enrichment of the complex of gadolinium with the hexaacid of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said higher complex to that obtained at the end of step b2) or at the end of step b3), when the latter is implemented prior to step b4).
L'étape b4) comprend typiquement les sous-étapes successives suivantes :
- mise en suspension du complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi isolé lors de l'étape b2) ou lors de l'étape b3) dans de l'eau,
- ajout d'une base, par exemple de soude,
- chauffage à une température avantageusement comprise entre 30°C et 60°C, notamment entre 35°C et 55°C, par exemple à 40°C, typiquement pendant une durée comprise entre 2h et 20h, notamment entre 10h et 18h,
- refroidissement à une température avantageusement comprise entre 10°C et 30°C, par exemple à 30°C, et
- isolement du complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi et purifié, par exemple par filtration et séchage.
- suspending the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) isolated during step b2) or during step b3) in water,
- addition of a base, for example soda,
- heating to a temperature advantageously between 30°C and 60°C, in particular between 35°C and 55°C, for example at 40°C, typically for a period of between 2h and 20h, in particular between 10h and 18h,
- cooling to a temperature advantageously between 10°C and 30°C, for example to 30°C, and
- isolation of the diastereoisomerically enriched and purified hexaacid gadolinium complex of formula (I), for example by filtration and drying.
L'étape b4) est rendue possible par le fait que les isomères I-RRR et I-SSS sont les plus stables en milieu basique. De telles conditions basiques favorisent la formation d'hydroxyde de gadolinium, et par conséquent la décomplexation des isomères les moins stables.Step b4) is made possible by the fact that the I-RRR and I-SSS isomers are the most stable in a basic medium. Such basic conditions favor the formation of gadolinium hydroxide, and consequently the decomplexation of the less stable isomers.
Ainsi, il convient de noter que, de manière surprenante, les isomères I-RRR et I-SSS sont plus stables à la fois en milieu acide, ce qui permet l'étape b1) d'isomérisation, et en milieu basique, ce qui permet l'étape b4) de décomplexation sélective.Thus, it should be noted that, surprisingly, the I-RRR and I-SSS isomers are more stable both in an acid medium, which allows step b1) of isomerization, and in a basic medium, which allows step b4) of selective decomplexation.
Dans un mode de réalisation préféré, le complexe diastéréoisomériquement enrichi obtenu à l'issue de l'étape b) selon l'une quelconque des variantes décrites ci-dessus présente au moins 85 %, notamment au moins 90 %, en particulier au moins 95 %, de préférence au moins 97 %, avantageusement au moins 98 %, plus avantageusement au moins 99 % de l'excès diastéréoisomérique comprenant le mélange des isomères I-RRR et I-SSS.In a preferred embodiment, the diastereoisomerically enriched complex obtained at the end of step b) according to any one of the variants described above has at least 85%, in particular at least 90%, in particular at least 95 %, preferably at least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of I-RRR and I-SSS isomers.
De préférence, ledit excès diastéréoisomérique est constitué d'au moins 70 %, notamment d'au moins 80 %, avantageusement d'au moins 90 %, de préférence d'au moins 95 % du mélange d'isomères I-RRR et I-SSS.Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
Avantageusement, ledit excès diastéréoisomérique consiste en le mélange d'isomères I-RRR et I-SSS.Advantageously, said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
Le terme « mélange d'isomères I-RRR et I-SSS » recouvre également, par extension, le cas où seul l'un des isomères, qu'il s'agisse du I-RRR ou du I-SSS, est présent. Toutefois, le terme « mélange d'isomères I-RRR et I-SSS » désigne préférentiellement l'ensemble des cas où chacun des isomères I-RRR et I-SSS est présent en une quantité variable mais non nulle.The term “mixture of I-RRR and I-SSS isomers” also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present. Nevertheless, the term “mixture of I-RRR and I-SSS isomers” preferably designates all the cases where each of the I-RRR and I-SSS isomers is present in a variable but non-zero amount.
Dans un mode de réalisation préféré, les isomères I-RRR et I-SSS sont présents au sein dudit mélange dans un rapport compris entre 65/35 et 35/65, notamment entre 60/40 et 40/60, en particulier entre 55/45 et 45/55. Avantageusement, le mélange de d'isomères I-RRR/I-SSS est un mélange racémique (50/50).In a preferred embodiment, the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/ 45 and 45/55. Advantageously, the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
L'étape c) vise à former le complexe de formule (II) à partir de son précurseur, le complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi obtenu lors de l'étape b).Step c) aims to form the complex of formula (II) from its precursor, the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) obtained during step b).
Au cours de cette étape, les trois fonctions acides carboxyliques du complexe hexaacide de formule (I) portées par les atomes de carbone situés en position γ sur les chaînes latérales du complexe, par rapport aux atomes d'azote du macrocycle sur lesquels sont greffées lesdites chaînes latérales, sont converties en fonctions amide, par réaction d'amidification avec le 3-amino-1,2-propanediol, sous forme racémique ou énantiomériquement pure, de préférence sous forme racémique.During this step, the three carboxylic acid functions of the hexaacid complex of formula (I) carried by the carbon atoms located in the γ position on the side chains of the complex, relative to the nitrogen atoms of the macrocycle on which the said side chains, are converted into amide functions, by amidation reaction with 3-amino-1,2-propanediol, in racemic or enantiomerically pure form, preferably in racemic form.
Cette réaction d'amidification ne modifie pas la configuration absolue des trois atomes de carbones asymétriques situés en position α sur les chaînes latérales, par rapport aux atomes d'azote du macrocycle sur lesquels sont greffées lesdites chaînes latérales. Par conséquent, l'étape c) permet d'obtenir le complexe de formule (II) avec un excès diastéréoisomérique comprenant un mélange des isomères II-RRR et II-SSS identique à l'excès diastéréoisomérique comprenant un mélange des isomères I-RRR et I-SSS avec lequel est obtenu le complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi obtenu à l'issue de l'étape b), qui est d'au moins 80 %.This amidation reaction does not modify the absolute configuration of the three asymmetric carbon atoms located in the α position on the side chains, with respect to the nitrogen atoms of the macrocycle on which the said side chains are grafted. Consequently, step c) makes it possible to obtain the complex of formula (II) with a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers identical to the diastereoisomeric excess comprising a mixture of I-RRR isomers and I-SSS with which is obtained the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) obtained at the end of step b), which is at least 80%.
Dans un mode de réalisation préféré, le complexe de formule (II) obtenu à l'issue de l'étape c) présente au moins 85 %, notamment au moins 90 %, en particulier au moins 92 %, de préférence au moins 94 %, avantageusement au moins 97 %, plus avantageusement au moins 99 % de l'excès diastéréoisomérique comprenant le mélange d'isomères II-RRR et II-SSS.In a preferred embodiment, the complex of formula (II) obtained at the end of step c) has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94% , advantageously at least 97%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
De préférence, ledit excès diastéréoisomérique est constitué d'au moins 70 %, notamment d'au moins 80 %, avantageusement d'au moins 90 %, de préférence d'au moins 95 % du mélange d'isomères II-RRR et II-SSS.Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
Avantageusement, ledit excès diastéréoisomérique consiste en le mélange d'isomères II-RRR et II-SSS.Advantageously, said diastereoisomeric excess consists of the mixture of II-RRR and II-SSS isomers.
Le terme « mélange d'isomères II-RRR et II-SSS » recouvre également, par extension, le cas où seul l'un des isomères, qu'il s'agisse du II-RRR ou du II-SSS, est présent. Toutefois, le terme « mélange d'isomères II-RRR et II-SSS » désigne préférentiellement l'ensemble des cas où chacun des isomères II-RRR et II-SSS est présent en une quantité variable mais non nulle.The term “mixture of II-RRR and II-SSS isomers” also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present. However, the term “mixture of II-RRR and II-SSS isomers” preferably designates all the cases where each of the II-RRR and II-SSS isomers is present in a variable but non-zero amount.
Dans un mode de réalisation préféré, les isomères II-RRR et II-SSS sont présents au sein dudit mélange dans un rapport compris entre 65/35 et 35/65, notamment entre 60/40 et 40/60, en particulier entre 55/45 et 45/55. Avantageusement, les isomères II-RRR et II-SSS sont présents au sein du mélange dans un rapport 50/50.In a preferred embodiment, the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/ 45 and 45/55. Advantageously, the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
La réaction d'amidification peut être effectuée selon toutes les méthodes bien connues de l'homme du métier, notamment en présence d'un agent activant des fonctions acides carboxyliques et/ou en catalyse acide.The amidation reaction can be carried out according to any method well known to those skilled in the art, in particular in the presence of an agent which activates carboxylic acid functions and/or in acid catalysis.
Elle peut notamment être réalisée selon les méthodes décrites dans le brevet
Dans un mode de réalisation particulier, l'étape c) comprend l'activation des fonctions acides carboxyliques (-COOH) du complexe hexaacide de formule (I) portées par les atomes de carbone situés en position γ sur les chaînes latérales du complexe, par rapport aux atomes d'azote du macrocycle sur lesquels sont greffées lesdites chaînes latérales, sous la forme de fonctions dérivées comportant un groupement carbonyle (C=O), qui sont telles que l'atome de carbone du groupement carbonyle est plus électrophile que l'atome de carbone du groupement carbonyle des fonctions acides carboxyliques. Ainsi, selon ce mode de réalisation particulier, lesdites fonctions acides carboxyliques peuvent notamment être activées sous la forme de fonctions esters, de chlorures d'acyle, d'anhydrides d'acide, ou sous toute forme activée susceptible de conduire à une liaison amide. Les formes activées susceptibles de conduire à une liaison amide sont bien connues de l'homme du métier et peuvent être par exemple obtenues par l'ensemble des méthodes connues en chimie peptidique pour créer une liaison peptidique. Des exemples de telles méthodes sont données dans la publication
De préférence, l'étape c) comprend l'activation des fonctions acides carboxyliques (-COOH) susmentionnées sous la forme de fonctions esters, chlorures d'acyle ou anhydrides d'acide.Preferably, step c) comprises the activation of the carboxylic acid functions (-COOH) mentioned above in the form of ester, acyl chloride or acid anhydride functions.
Ce mode de réalisation est préféré au couplage peptidique par activation de la fonction acide carboxylique à l'aide d'un agent de couplage tel que EDCI/HOBT comme décrit dans le document
Par« fonction ester », on entend désigner au sens de la présente invention un groupement -C(O)O-. Il peut s'agir en particulier d'un groupement -C(O)O-R1, dans lequel R1 correspond à un groupement (C1-C6)alkyle.By “ester function” is meant, within the meaning of the present invention, a —C(O)O— group. It may in particular be a —C(O)OR 1 group, in which R 1 corresponds to a (C 1 -C 6 )alkyl group.
Par groupement « (C1-C6)alkyle », on entend, au sens de la présente invention, une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comportant 1 à 6, de préférence 1 à 4, atomes de carbone. A titre d'exemple, on peut citer les groupes méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, sec-butyle, tert-butyle, pentyle ou encore hexyle.By “(C 1 -C 6 )alkyl” group is meant, within the meaning of the present invention, a saturated hydrocarbon chain, linear or branched, comprising 1 to 6, preferably 1 to 4, carbon atoms. By way of example, mention may be made of the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or even hexyl groups.
Par « fonction chlorure d'acyle », également appelée « fonction chlorure d'acide », on entend désigner au sens de la présente invention un groupement -CO-CI.By “acyl chloride function”, also called “acid chloride function”, is meant within the meaning of the present invention a —CO—CI group.
Par « fonction anhydride d'acide », on entend désigner au sens de la présente invention un groupement -CO-O-CO-. Il peut s'agir en particulier d'un groupement -CO-O-CO-R2, dans lequel R2 correspond à un groupement (C1-C6)alkyle.By “acid anhydride function” is meant, within the meaning of the present invention, a —CO—O—CO— group. It may in particular be a —CO—O—CO—R 2 group, in which R 2 corresponds to a (C 1 -C 6 )alkyl group.
Les réactions de conversion d'une fonction acide carboxylique en fonction ester, chlorure d'acyle ou anhydride d'acide sont bien connues de l'homme du métier, qui pourra les mettre en œuvre selon toute méthode usuelle dont il est familier.The conversion reactions of a carboxylic acid function into an ester, acyl chloride or acid anhydride function are well known to those skilled in the art, who can implement them according to any usual method with which they are familiar.
Le complexe de formule (II) est ensuite obtenu par aminolyse des fonctions acides carboxyliques activées sous la forme de fonctions esters, chlorures d'acyle ou anhydrides d'acide, notamment esters ou anhydrides d'acide, de préférence esters, par réaction avec le 3-amino-1,2-propanediol, sous forme racémique ou énantiomériquement pure, de préférence sous forme racémique.The complex of formula (II) is then obtained by aminolysis of the carboxylic acid functions activated in the form of ester functions, acyl chlorides or acid anhydrides, in particular esters or acid anhydrides, preferably esters, by reaction with the 3-Amino-1,2-propanediol, in racemic or enantiomerically pure form, preferably in racemic form.
De manière préférentielle, les étapes d'activation des fonctions acides carboxyliques et d'aminolyse sont effectuées selon un mode de réalisation monotope (ou « one-pot » en anglais), c'est-à-dire dans le même réacteur et sans étape intermédiaire d'isolement ou de purification de l'intermédiaire comportant les fonctions acides carboxyliques activées sous la forme de fonctions esters, chlorures d'acyle ou anhydrides d'acide, notamment esters ou anhydrides d'acide, de préférence esters.Preferably, the steps of activating the carboxylic acid functions and of aminolysis are carried out according to a one-pot embodiment, that is to say in the same reactor and without step intermediate for isolating or purifying the intermediate comprising the carboxylic acid functions activated in the form of esters, acyl chlorides or acid anhydrides, in particular esters or acid anhydrides, preferably esters.
Selon un mode de réalisation particulier, l'étape c) comprend les étapes successives suivantes :
- c1) formation d'un complexe activé de formule (VII),
- c2) aminolyse du complexe activé de formule (VII) avec le 3-amino-1,2-propanediol.
- c1) formation of an activated complex of formula (VII),
- c2) aminolysis of the activated complex of formula (VII) with 3-amino-1,2-propanediol.
Comme cela apparaîtra clairement à l'homme du métier, la réaction de formation du complexe activé de formule (VII) ne modifie pas la configuration absolue des trois atomes de carbones asymétriques situés en position α sur les chaînes latérales, par rapport aux atomes d'azote du macrocycle sur lesquels sont greffées lesdites chaînes latérales. Par conséquent, l'étape c1) permet d'obtenir le complexe activé de formule (VII) avec un excès diastéréoisomérique comprenant un mélange des isomères VII-RRR et VII-SSS, de formules (VII-RRR) et (VII-SSS) représentées ci-après, identique à l'excès diastéréoisomérique comprenant un mélange des isomères I-RRR et I-SSS avec lequel est obtenu le complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi obtenu à l'issue de l'étape b), qui est d'au moins 80 %.
Dans le cas où Y représente un atome de chlore, l'étape c1) est typiquement réalisée par réaction entre le complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi obtenu lors de l'étape b) et le chlorure de thionyle (SOCl2).In the case where Y represents a chlorine atom, step c1) is typically carried out by reaction between the gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched obtained during step b) and thionyl chloride (SOCl 2 ).
Dans le cas où Y représente un groupement -O-C(O)-CH3, l'étape c1) est typiquement réalisée par réaction entre le complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi obtenu lors de l'étape b) et le chlorure d'acétyle.In the case where Y represents an -OC(O)-CH 3 group, step c1) is typically carried out by reaction between the diastereoisomerically enriched gadolinium complex of hexaacid of formula (I) obtained during step b) and acetyl chloride.
Dans un mode de réalisation avantageux, l'étape c) comprend l'activation des fonctions acides carboxyliques (-COOH) susmentionnées sous la forme de fonctions esters.In an advantageous embodiment, step c) comprises the activation of the carboxylic acid functions (-COOH) mentioned above in the form of ester functions.
Selon ce mode de réalisation, l'étape c) peut plus particulièrement comprendre les étapes successives suivantes :
- c1) formation d'un triester de formule (VIII),
- c2) aminolyse du triester de formule (VIII) avec le 3-amino-1,2-propanediol.
- c1) formation of a triester of formula (VIII),
- c2) aminolysis of the triester of formula (VIII) with 3-amino-1,2-propanediol.
L'étape c1) est typiquement réalisée dans l'alcool de formule R1OH, qui joue à la fois le rôle de solvant et de réactif, en présence d'un acide tel que l'acide chlorhydrique.Step c1) is typically carried out in the alcohol of formula R 1 OH, which plays both the role of solvent and reagent, in the presence of an acid such as hydrochloric acid.
Dans un premier temps, le complexe de gadolinium d'hexaacide de formule (I) et l'alcool R1OH sont chargés dans le réacteur. Le milieu réactionnel est ensuite refroidi à une température inférieure à 10°C, notamment inférieure à 5 °C, typiquement à 0°C, et une solution acide de l'alcool R1OH, typiquement d'acide chlorhydrique dans R1OH est alors progressivement ajoutée. Le milieu réactionnel est maintenu sous agitation à température ambiante (c'est-à-dire à une température entre 20 et 25°C) pendant une durée typiquement supérieure à 5h, de préférence comprise entre 10h et 20h. Le milieu réactionnel est refroidi à une température inférieure à 10°C, notamment comprise entre 0°C et 5 °C, préalablement à l'étape c2).First, the hexaacid gadolinium complex of formula (I) and the alcohol R 1 OH are loaded into the reactor. The reaction medium is then cooled to a temperature below 10°C, in particular below 5°C, typically at 0°C, and an acid solution of the alcohol R 1 OH, typically of hydrochloric acid in R 1 OH is then gradually added. The reaction medium is kept stirred at room temperature (that is to say at a temperature between 20 and 25° C.) for a period typically greater than 5 hours, preferably between 10 hours and 20 hours. The reaction medium is cooled at a temperature below 10° C., in particular between 0° C. and 5° C., prior to step c2).
L'étape c2) est également typiquement réalisée dans l'alcool de formule R1OH, en présence d'un acide tel que l'acide chlorhydrique.Step c2) is also typically carried out in the alcohol of formula R 1 OH, in the presence of an acid such as hydrochloric acid.
Ainsi, les étapes c1) et c2) peuvent être aisément mises en œuvre selon un mode de réalisation monotope (ou « one-pot » en anglais). Avantageusement, le triester de formule (VII) n'est pas isolé entre les étapes c1) et c2).Thus, steps c1) and c2) can easily be implemented according to a one-pot embodiment. Advantageously, the triester of formula (VII) is not isolated between steps c1) and c2).
Toutefois, afin de favoriser la réaction d'aminolyse, au cours de l'étape c2), l'alcool de formule R1OH est de préférence éliminé par distillation sous vide.However, in order to promote the aminolysis reaction, during step c2), the alcohol of formula R 1 OH is preferably removed by vacuum distillation.
Par « distillation sous vide », on entend, au sens de la présente invention, la distillation d'un mélange réalisée à une pression comprise entre 10 et 500 mbar, notamment entre 10 et 350 mbar, de préférence entre 10 et 150 mbar, en particulier entre 50 et 100 mbar.By "vacuum distillation" is meant, within the meaning of the present invention, the distillation of a mixture carried out at a pressure of between 10 and 500 mbar, in particular between 10 and 350 mbar, preferably between 10 and 150 mbar, in particular between 50 and 100 mbar.
De même, afin de favoriser la réaction d'aminolyse, lors de l'étape c2), le 3-amino-1,2-propanediol est introduit en large excès. Typiquement, la quantité de matière de 3-amino-1,2-propanediol introduite est supérieure à 4 éq., notamment supérieure 7 éq., avantageusement supérieure à 10 éq., par rapport à la quantité de matière de complexe de gadolinium d'hexaacide de formule (I) diastéréoisomériquement enrichi initialement introduite au cours de l'étape c), qui correspond quant à elle à 1 équivalent.Similarly, in order to promote the aminolysis reaction, during step c2), 3-amino-1,2-propanediol is introduced in large excess. Typically, the amount of material of 3-amino-1,2-propanediol introduced is greater than 4 eq., in particular greater than 7 eq., advantageously greater than 10 eq., relative to the amount of material of gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched initially introduced during step c), which corresponds to 1 equivalent.
De manière surprenante, en dépit des conditions acides typiquement employées au cours des étapes c1) et c2), qui devraient augmenter l'instabilité cinétique des complexes de gadolinium, on n'observe pas de décomplexation ou d'isomérisation du triester de formule (VIII). Le triamide désiré est obtenu avec un très bon taux de conversion et la configuration absolue des trois atomes de carbones asymétriques situés en position α sur les chaînes latérales, par rapport aux atomes d'azote du macrocycle, est conservée.Surprisingly, despite the acidic conditions typically employed during steps c1) and c2), which should increase the kinetic instability of the gadolinium complexes, no decomplexation or isomerization of the triester of formula (VIII ). The desired triamide is obtained with a very good conversion rate and the absolute configuration of the three asymmetric carbon atoms located in the α position on the side chains, with respect to the nitrogen atoms of the macrocycle, is preserved.
Par ailleurs, il est à noter que, de manière générale, les réactions d'amidification par réaction directe entre un ester et une amine sont très peu décrites dans la littérature (voir à ce sujet
Dans un mode de réalisation préféré, l'étape c) comprend les étapes successives suivantes :
- c1) formation d'un triester de méthyle de formule (IV),
- c2) aminolyse du triester de méthyle de formule (IV) avec le 3-amino-1,2-propanediol, notamment dans du méthanol en présence d'un acide tel que l'acide chlorhydrique.
- c1) formation of a methyl triester of formula (IV),
- c2) aminolysis of the methyl triester of formula (IV) with 3-amino-1,2-propanediol, in particular in methanol in the presence of an acid such as hydrochloric acid.
Avantageusement, le triester de méthyle de formule (IV) n'est pas isolé entre les étapes c1) et c2).Advantageously, the methyl triester of formula (IV) is not isolated between steps c1) and c2).
Dans un mode de réalisation préféré, au cours de l'étape c2), le méthanol est éliminé par distillation sous vide, jusqu'à atteindre une température typiquement supérieure à 55°C, notamment comprise entre 60°C et 65°C, et le milieu réactionnel est maintenu à cette température sous vide pendant une durée typiquement supérieure à 5h, notamment comprise entre 10h et 20h, avant d'être refroidi à température ambiante et dilué avec de l'eau.In a preferred embodiment, during step c2), the methanol is removed by distillation under vacuum, until a temperature typically greater than 55° C., in particular between 60° C. and 65° C., is reached, and the reaction medium is maintained at this temperature under vacuum for a period typically greater than 5 h, in particular between 10 h and 20 h, before being cooled to ambient temperature and diluted with water.
La présente invention englobe toutes les combinaisons des modes de réalisations particuliers, avantageux ou préférés décrits ci-dessus en lien avec chaque étape du procédé.The present invention encompasses all the combinations of the particular, advantageous or preferred embodiments described above in connection with each step of the method.
Dans un mode de réalisation préféré, le procédé selon l'invention implique donc un complexe de gadolinium de triester de formule (VIII) :
Par « excès diastéréoisomérique » on entend désigner, dans le cadre de la présente invention, et en ce qui concerne le complexe de gadolinium de triester de formule (VIII), le fait que ledit complexe est majoritairement présent sous la forme d'un isomère ou groupe d'isomères choisi(s) parmi les diastéréoisomères VIII-RRR, VIII-SSS, VIII-RRS, VIII-SSR, VIII-RSS, VIII-SRR, VIII-RSR et VIII-SRS. Ledit excès diastéréoisomérique est exprimé en pourcentage, et correspond à la quantité que représente l'isomère ou le groupe d'isomères majoritaire par rapport à la quantité totale du complexe de triester de formule (VIII). Il est entendu que ce pourcentage peut être aussi bien molaire que massique, dans la mesure où des isomères ont, par définition, la même masse molaire.By "diastereoisomeric excess" is meant, in the context of the present invention, and with regard to the triester gadolinium complex of formula (VIII), the fact that said complex is predominantly present in the form of an isomer or group of isomers chosen from the VIII-RRR, VIII-SSS, VIII-RRS, VIII-SSR, VIII-RSS, VIII-SRR, VIII-RSR and VIII-SRS diastereoisomers. Said diastereoisomeric excess is expressed as a percentage, and corresponds to the quantity represented by the predominant isomer or group of isomers relative to the total quantity of the triester complex of formula (VIII). He is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
Dans un mode de réalisation particulier du procédé selon l'invention, le complexe de gadolinium de triester de formule (VIII) selon l'invention présente au moins 85%, notamment au moins 90 %, en particulier au moins 95 %, de préférence au moins 97 %, avantageusement au moins 98 %, plus avantageusement au moins 99 % de l'excès diastéréoisomérique comprenant le mélange d'isomères VIII-RRR et VIII-SSS.In a particular embodiment of the process according to the invention, the triester gadolinium complex of formula (VIII) according to the invention has at least 85%, in particular at least 90%, in particular at least 95%, preferably at least least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of VIII-RRR and VIII-SSS isomers.
De préférence, ledit excès diastéréoisomérique est constitué d'au moins 70 %, notamment d'au moins 80 %, avantageusement d'au moins 90 %, de préférence d'au moins 95 % du mélange d'isomères VIII-RRR et VIII-SSS.Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of isomers VIII-RRR and VIII- SSS.
Avantageusement, ledit excès diastéréoisomérique consiste en le mélange d'isomères VIII-RRR et VIII-SSS.Advantageously, said diastereoisomeric excess consists of the mixture of VIII-RRR and VIII-SSS isomers.
Le terme « mélange d'isomères VIII-RRR et VIII-SSS » recouvre également le cas où seul l'un des isomères, qu'il s'agisse du VIII-RRR ou du VIII-SSS, est présent. Toutefois, le terme « mélange d'isomères VIII-RRR et VIII-SSS » désigne préférentiellement l'ensemble des cas où chacun des isomères VIII-RRR et VIII-SSS est présent en une quantité variable mais non nulle.The term “mixture of VIII-RRR and VIII-SSS isomers” also covers the case where only one of the isomers, whether it be VIII-RRR or VIII-SSS, is present. However, the term “mixture of VIII-RRR and VIII-SSS isomers” preferably designates all the cases where each of the VIII-RRR and VIII-SSS isomers is present in a variable but non-zero quantity.
Dans un mode de réalisation préféré du procédé selon l'invention, les isomères VIII-RRR et VIII-SSS sont présents au sein dudit mélange dans un rapport compris entre 65/35 et 35/65, notamment entre 60/40 et 40/60, en particulier entre 55/45 et 45/55. Avantageusement, le mélange de d'isomères VIII-RRR/VIII-SSS est un mélange racémique (50/50).In a preferred embodiment of the process according to the invention, the VIII-RRR and VIII-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60 , in particular between 55/45 and 45/55. Advantageously, the mixture of VIII-RRR/VIII-SSS isomers is a racemic mixture (50/50).
Dans un mode de réalisation préféré du procédé selon l'invention, le complexe de gadolinium de triester de formule (VIII) est un complexe de gadolinium de triméthyle, c'est-à-dire complexe de gadolinium de triester de formule (VIII) dans laquelle R1 est un groupement méthyle (CH3).In a preferred embodiment of the process according to the invention, the triester gadolinium complex of formula (VIII) is a trimethyl gadolinium complex, that is to say a triester gadolinium complex of formula (VIII) in which R 1 is a methyl group (CH 3 ).
L'hexaacide de formule (III), qui intervient lors de l'étape a) du procédé de préparation du complexe de formule (II) selon l'invention, peut être préparé selon toutes les méthodes d'ores et déjà connues et notamment selon les méthodes décrites dans le brevet
Toutefois, selon un mode de réalisation préféré, l'hexaacide de formule (III) est obtenu par alkylation du pyclène de formule (V) :
- R3 et R4 représentent, indépendamment l'un de l'autre, un groupe (C3-C6)alkyle, notamment un groupe (C4-C6)alkyle tel qu'un groupement butyle, isobutyle, sec-butyle, tert-butyle, pentyle ou encore hexyle, et
- Gp représente un groupe partant tel qu'un groupement tosylate, triflate, ou un atome d'halogène, de préférence un atome de brome,
- R 3 and R 4 represent, independently of one another, a (C 3 -C 6 )alkyl group, in particular a (C 4 -C 6 )alkyl group such as a butyl, isobutyl or sec-butyl group , tert-butyl, pentyl or even hexyl, and
- G p represents a leaving group such as a tosylate or triflate group, or a halogen atom, preferably a bromine atom,
Dans un mode de réalisation préféré, R3 et R4 sont identiques.In a preferred embodiment, R 3 and R 4 are identical.
Selon un mode de réalisation avantageux, l'hexaacide de formule (III) est obtenu par alkylation du pyclène de formule (V) :
Le 2-bromoglutarate de dibutyle utilisé est sous forme racémique ou énantiomériquement pure, de préférence sous forme racémique.The dibutyl 2-bromoglutarate used is in racemic or enantiomerically pure form, preferably in racemic form.
L'utilisation du 2-bromoglutarate de dibutyle est particulièrement avantageuse, en comparaison à celle du 2-bromoglutarate d'éthyle décrite dans le document
La réaction d'alkylation est typiquement réalisée dans un solvant polaire, de préférence dans l'eau, en particulier dans de l'eau désionisée, avantageusement en présence d'une base telle que le carbonate de potassium ou de sodium.The alkylation reaction is typically carried out in a polar solvent, preferably in water, in particular in deionized water, advantageously in the presence of a base such as potassium or sodium carbonate.
L'utilisation d'eau est préférée notamment à celle d'acétonitrile, décrite dans le document
La réaction est avantageusement conduite à une température comprise entre 40°C et 80°C, typiquement entre 50°C et 70°C, notamment entre 55°C et 60°C, pendant une durée comprise entre 5h et 20h, en particulier entre 8h et 15h.The reaction is advantageously carried out at a temperature between 40° C. and 80° C., typically between 50° C. and 70° C., in particular between 55° C. and 60° C., for a period of between 5 h and 20 h, in particular between 8 a.m. and 3 p.m.
L'étape d'hydrolyse est réalisée avantageusement en présence d'un acide ou d'une base, avantageusement d'une base telle que la soude. Le solvant d'hydrolyse peut être de l'eau, un alcool tel que l'éthanol, ou un mélange eau/alcool. Cette étape est conduite avantageusement à une température comprise entre 40°C et 80°C, typiquement entre 40°C et 70°C, notamment entre 50°C et 60°C, typiquement pendant une durée comprise entre 10h et 30h, en particulier entre 15h et 25h.The hydrolysis step is advantageously carried out in the presence of an acid or a base, advantageously a base such as sodium hydroxide. The hydrolysis solvent can be water, an alcohol such as ethanol, or a water/alcohol mixture. This step is advantageously carried out at a temperature of between 40°C and 80°C, typically between 40°C and 70°C, in particular between 50°C and 60°C, typically for a period of between 10h and 30h, in particular between 3 p.m. and 10 p.m.
Dans un mode de réalisation préféré, le procédé selon l'invention implique donc l'hexaester de butyle de formule (VI) :
En effet, cet hexaester se distingue par une stabilité nettement améliorée par rapport aux esters ayant une chaîne alkyle plus courte, notamment par rapport à l'hexaester d'éthyle décrit dans le document
Les exemples figurant ci-après sont présentés à titre illustratif et non limitatif de l'invention.The examples given below are presented by way of non-limiting illustration of the invention.
Un appareil HPLC constitué d'un système de pompage, d'un injecteur, d'une colonne chromatographique, d'un détecteur spectrophotométrique UV et d'une station de pilotage et de traitement des données est utilisé. La colonne chromatographique utilisée est une colonne C18 - 250 x 4,6 mm - 5 µm (gamme Symmetry®, de Waters).An HPLC apparatus consisting of a pumping system, an injector, a chromatographic column, a UV spectrophotometric detector and a control and data processing station is used. The chromatographic column used is a C18 column - 250×4.6 mm - 5 μm (Symmetry® range , from Waters).
Voie A : 100% acétonitrile et Voie B : solution aqueuse d'H2SO4 (96 %) à 0,1 % v/vRoute A: 100% acetonitrile and Route B: aqueous solution of H2SO4 (96%) at 0.1% v/v
Solution du complexe de gadolinium d'hexaacide de formule (I) à 10 mg/mL dans l'eau purifiée.
- Conditions d'analyse :
- Gradient :
% H2SO4 0,1 % : % v/v de la solution de H2SO4 à 0,1% v/v dans la phase mobile
- Analysis conditions :
- Gradient :
% H 2 SO 4 0.1%: % v/v of the solution of H 2 SO 4 at 0.1% v/v in the mobile phase
4 pics principaux sont obtenus. Le pic 4 de la trace HPLC, à savoir l'isoD, correspond à un temps de rétention de 35,7 minutes.4 main peaks are obtained.
Un appareil UHPLC constitué d'un système de pompage, d'un injecteur, d'une colonne chromatographique, d'un détecteur UV et d'une station de données est utilisé. La colonne chromatographique utilisée est une colonne UHPLC 150 x 2,1 mm -1,8 µm (colonne ACQUITY UPLC HSS T3 de Waters). Il s'agit d'une colonne UPLC en phase inverse à particules sphériques constituées de silice avec un greffage C18 (octadécyl) trifonctionnel, et dont les silanols ont été traités par des agents de coiffage (end-capped). Elle est en outre caractérisée par une longueur de 150 mm, un diamètre intérieur de 2,1 mm, une granulométrie de 1,8 µm, une porosité de 100 Å et un taux de carbone de 11%.A UHPLC apparatus consisting of a pumping system, an injector, a chromatographic column, a UV detector and a data station is used. The chromatographic column used is a 150×2.1 mm −1.8 μm UHPLC column (ACQUITY UPLC HSS T3 column from Waters). It is a reversed-phase UPLC column with spherical particles made of silica with a trifunctional C18 (octadecyl) grafting, and whose silanols have been treated with capping agents (end-capped). It is further characterized by a length of 150 mm, an internal diameter of 2.1 mm, a particle size of 1.8 µm, a porosity of 100 Å and a carbon content of 11%.
De manière préférentielle, la phase stationnaire utilisée doit être compatible avec les phases mobiles aqueuses.
- Phase mobile :
Voie A: 100% acétonitrile et Voie B : solution aqueuse d'H2SO4 (96 %) à 0,1 % v/v
- Préparation des solutions essais :
Solution du complexe de gadolinium d'hexaacide de formule (I) à 0,8 mg/mL dans de l'eau purifiée
- Conditions d'analyse :
- Gradient :
- Moving phase :
Route A: 100% acetonitrile and Route B: aqueous solution of H 2 SO 4 (96%) at 0.1% v/v
- Preparation of test solutions :
Solution of the hexaacid gadolinium complex of formula (I) at 0.8 mg/mL in purified water
- Analysis conditions :
- Gradient :
4 pics principaux sont obtenus. Le pic 4 de la trace UHPLC, à savoir l'isoD, correspond à un temps de rétention de 17,4 minutes.4 main peaks are obtained.
Un appareil UHPLC constitué d'un système de pompage, d'un injecteur, d'une colonne chromatographique, d'un détecteur UV et d'une station de données est utilisé. La colonne chromatographique utilisée est une colonne UHPLC 150 x 2,1 mm -1,6 µm (colonne CORTECS® UPLC T3 de Waters).
- Phase mobile :
Voie A : 100% acétonitrile et Voie B : solution aqueuse d'H2SO4 (96 %) à 0,0005 % v/v
- Préparation des solutions essais :
Solution du complexe de formule (II) à 2 mg/mL dans de l'eau purifiée
- Conditions d'analyse :
- Gradient :
- Moving phase :
Route A: 100% acetonitrile and Route B: aqueous solution of H 2 SO 4 (96%) at 0.0005% v/v
- Preparation of test solutions :
Solution of the complex of formula (II) at 2 mg/mL in purified water
- Analysis conditions :
- Gradient :
4 pics principaux sont obtenus. Le pic 4 de la trace UHPLC, à savoir l'iso4, correspond à un temps de rétention de 6,3 minutes.4 main peaks are obtained.
Les temps de relaxation T1 et T2 ont été déterminés par des procédures standards sur un appareil Minispec® mq20 (Bruker) à 20 Mhz (0,47 T), à 60 Mhz (1,41 T) et 37°C. Le temps de relaxation longitudinal T1 est mesuré en utilisant une séquence d'Inversion Récupération et le temps de relaxation transverse T2 est mesuré par une technique CPMG (Carr-Purcell-Meiboom-Gill).The relaxation times T 1 and T 2 were determined by standard procedures on a Minispec ® mq20 apparatus (Bruker) at 20 MHz (0.47 T), at 60 MHz (1.41 T) and 37°C. The longitudinal relaxation time T 1 is measured using an Inversion Recovery sequence and the transverse relaxation time T 2 is measured by a CPMG (Carr-Purcell-Meiboom-Gill) technique.
Les vitesses de relaxation R1 (= 1/T1) et R2 (= 1/T2) ont été calculées pour différentes concentrations en métal total (variant de 0,5 x 10-3 à 5 x 10-3 mole/L) en solution aqueuse à 37°C. La corrélation entre R1 ou R2 en fonction de la concentration est linéaire, et la pente représente la relaxivité r1 (R1/C) ou r2 (R2/C) exprimées en (1 / seconde) x (1/ mMole/L) soit (mM-1.s-1).The relaxation rates R 1 (= 1/T 1 ) and R 2 (= 1/T 2 ) were calculated for different concentrations of total metal (varying from 0.5 x 10 -3 to 5 x 10 -3 mol/ L) in aqueous solution at 37°C. The correlation between R 1 or R 2 as a function of the concentration is linear, and the slope represents the relaxivity r 1 (R 1 /C) or r 2 (R 2 /C) expressed in (1 / second) x (1/ mMole/L) or (mM -1 .s -1 ).
La dissociation des complexes de gadolinium présents dans les 4 massifs d'isomères iso1 à iso4 (C = 8.10-6 M) est étudiée à 37°C, pH 1,2, dans une solution d'acide chlorhydrique dans des conditions de cinétique de pseudo premier ordre sans contrôle de la force ionique en suivant la libération du gadolinium dans la solution. La quantité de gadolinium libre a été déterminée par spectrométrie à 654 nm après ajout d'une solution d'Arsenazo III (C = 5,3.10-4 M).The dissociation of the gadolinium complexes present in the 4 masses of iso1 to iso4 isomers (C = 8.10-6 M) is studied at 37°C, pH 1.2, in a hydrochloric acid solution under kinetic conditions of pseudo first order without ionic strength control by following the release of gadolinium into solution. The quantity of free gadolinium was determined by spectrometry at 654 nm after adding a solution of Arsenazo III (C=5.3×10 −4 M).
Les temps de demi-vie (T1/2) qui ont été déterminées pour chacun des groupes d'isomères sont rappelés dans le tableau ci-dessous :
Le complexe de formule (II) sera appelé PA dans la suite de cet exemple.The complex of formula (II) will be called PA in the remainder of this example.
Les cinétiques de dégradation des massifs d'isomères iso1 à iso4, désignés par le terme générique isoX sont évaluées par mesure de la pureté HPLC et par le suivi de l'aire de chaque massif d'isomères au cours du temps. Les grandeurs mesurées sont ainsi : - P HPLC (temps), et
Les conditions de dégradation choisies sont les suivantes : [PA] = 1 mM dans la soude à 0,1 N. Dans ces conditions de dilution, l'impact de la dégradation du PA sur le milieu expérimental est faible. Les produits de dégradation ne modifient pas le pH du milieu, ce paramètre étant critique dans l'étude des cinétiques de dégradation. Ceci est confirmé expérimentalement par la mesure de pH initial et en fin de dégradation (72 heures, 37°C) :
Le mode de préparation des solutions est décrit ci-après :
peser environ 0,05 g de chaque produit qsp 10 mL de l'eau mQ, pour obtenir une solution A telle que [PA]A = 5 mM,- dilution : 2 mL de solution A qsp 10 mL NaOH (0,1 N), pour obtenir une solution B telle que [PA]B = 1 mM et [NaOH] = 0.08 M,
- aliquote des solutions dans des flacons HPLC, et
- incubation des flacons HPLC contenant les solutions de PA dans NaOH à la température de l'étude (37°C).
- weigh approximately 0.05 g of each product qsp 10 mL of mQ water, to obtain a solution A such that [PA] A = 5 mM,
- dilution: 2 mL of solution A qs 10 mL NaOH (0.1 N), to obtain a solution B such that [PA] B = 1 mM and [NaOH] = 0.08 M,
- aliquot solutions into HPLC vials, and
- incubation of the HPLC flasks containing the solutions of PA in NaOH at the temperature of the study (37° C.).
Pour chaque point, un aliquote est prélevé et analysé en HPLC sans dilution de l'échantillon (méthode acétate d'ammonium).For each point, an aliquot is taken and analyzed by HPLC without diluting the sample (ammonium acetate method).
Les résultats obtenus sont reportés en
Dans un réacteur, 184 kg (570 moles) de 2-bromoglutarate de dibutyle et 89 kg (644 moles) de carbonate de potassium sont mélangés et chauffés à 55-60°C. Une solution aqueuse de 29,4 kg (143 moles) de pyclène dans 24 kg d'eau est ajoutée à la préparation précédente. Le mélange réactionnel est maintenu à 55-60°C puis est chauffé à reflux une dizaine d'heures. Après réaction, le milieu est refroidi, dilué avec 155 kg de toluène puis lavé avec 300 litres d'eau. L'hexaester de butyle est extrait en phase aqueuse avec 175 kg (1340 moles) d'acide phosphorique (75%). Il est ensuite lavé 3 fois avec 150 kg de toluène. L'hexaester de butyle est reextrait en phase toluènique par dilution avec 145 kg de toluène et 165 kg d'eau suivie d'une basification à la soude 30 % (m/m) pour atteindre un pH de 5-5,5. La phase aqueuse inférieure est éliminée. L'hexaester de butyle est obtenu par concentration à sec sous vide à 60°C avec un rendement d'environ 85 %.In a reactor, 184 kg (570 moles) of dibutyl 2-bromoglutarate and 89 kg (644 moles) of potassium carbonate are mixed and heated to 55-60°C. An aqueous solution of 29.4 kg (143 moles) of pyclene in 24 kg of water is added to the previous preparation. The reaction mixture is maintained at 55-60° C. and then heated under reflux for about ten hours. After reaction, the medium is cooled, diluted with 155 kg of toluene then washed with 300 liters of water. The butyl hexaester is extracted in the aqueous phase with 175 kg (1340 moles) of phosphoric acid (75%). It is then washed 3 times with 150 kg of toluene. The butyl hexaester is reextracted in the toluene phase by dilution with 145 kg of toluene and 165 kg of water followed by basification with 30% (m/m) soda to reach a pH of 5-5.5. The lower aqueous phase is removed. The butyl hexaester is obtained by concentration to dryness under vacuum at 60° C. with a yield of approximately 85%.
Dans un réacteur, 113 kg (121 moles) d'hexaester de butyle sont chargés ainsi que 8 kg d'éthanol. Le milieu est porté à 55+/-5°C puis 161 kg (1207.5 moles) de soude 30 % (m/m) sont coulés en 3 heures. Le mélange réactionnel est maintenu à cette température pendant une vingtaine d'heures. Le butanol est ensuite retiré par décantation du milieu réactionnel. L'hexaacide de formule (III) obtenu sous forme de sel de sodium est dilué avec de l'eau pour obtenir une solution aqueuse d'environ 10 % (m/m). Cette solution est traitée sur une résine cationique acide. L'hexaacide de formule (III) en solution aqueuse est obtenu avec un rendement d'environ 90 % et une pureté de 95 %.In a reactor, 113 kg (121 moles) of butyl hexaester are loaded as well as 8 kg of ethanol. The medium is brought to 55+/-5° C. then 161 kg (1207.5 moles) of 30% (m/m) sodium hydroxide are poured in over 3 hours. The reaction mixture is maintained at this temperature for about twenty hours. The butanol is then removed by decantation from the reaction medium. The hexaacid of formula (III) obtained in the form of sodium salt is diluted with water to obtain an aqueous solution of about 10% (m/m). This solution is treated on an acid cationic resin. The hexaacid of formula (III) in aqueous solution is obtained with a yield of approximately 90% and a purity of 95%.
Dans un réacteur 418 kg (117 kg d'hexaacide de formule (III) pur / 196 moles) d'une solution aqueuse d'hexaacide de formule (III) à 28 % en poids sont chargés. Le pH de la solution est ajusté à 2,7 par ajout d'acide chlorhydrique, puis 37 kg (103,2 moles) d'oxyde de gadolinium sont ajoutés. Le milieu réactionnel est chauffé à 100-102°C pendant 48H pour atteindre la répartition isomérique attendue de l'hexaacide de formule (III).418 kg (117 kg of pure hexaacid of formula (III)/196 mol) of an aqueous solution of hexaacid of formula (III) at 28% by weight are loaded into a reactor. The pH of the solution is adjusted to 2.7 by adding hydrochloric acid, then 37 kg (103.2 moles) of gadolinium oxide are added. The reaction medium is heated at 100-102° C. for 48 hours to achieve the expected isomeric distribution of the hexaacid of formula (III).
De l'oxyde de gadolinium (0,525 éq. molaire) est mis en suspension dans une solution d'hexaacide de formule (III) à 28,1 % massique.Gadolinium oxide (0.525 molar eq.) is suspended in a solution of hexaacid of formula (III) at 28.1% by weight.
L'acide acétique 99-100 % (50 % massique / hexaacide de formule (III) pur) est coulé sur le milieu à température ambiante.The 99-100% acetic acid (50% by mass/pure hexaacid of formula (III)) is poured onto the medium at room temperature.
Le milieu est chauffé à reflux puis distillation jusqu'à 113°C en masse en rechargeant le milieu avec de l'acide acétique au fur et à mesure de l'élimination de l'eau. Arrivé à 113°C, on rajoute la quantité suffisante d'acide acétique afin d'arriver au volume de départ.The medium is heated to reflux and then distilled to 113° C. by mass, reloading the medium with acetic acid as the water is eliminated. Arrived at 113° C., a sufficient quantity of acetic acid is added in order to arrive at the starting volume.
Le milieu est maintenu à 113°C pendant une nuit.The medium is maintained at 113° C. overnight.
Le complexe de gadolinium d'hexaacide de formule (I) en solution est refroidi à 40°C, l'amorce est ajoutée, on laisse en contact pendant au moins 2h. Il est ensuite isolé par filtration à 40°C et lavé avec de l'eau osmosée.The hexaacid gadolinium complex of formula (I) in solution is cooled to 40° C., the primer is added, the mixture is left in contact for at least 2 hours. It is then isolated by filtration at 40° C. and washed with osmosed water.
180 kg du complexe de gadolinium d'hexaacide de formule (I) obtenu précédemment (extrait sec à environ 72%) sont mis en suspension dans 390 kg d'eau. Le milieu est chauffé à 100°C pour solubiliser le produit, puis refroidi à 80°C pour être amorcé en ajoutant un peu d'amorce. Après refroidissement à température ambiante le complexe de gadolinium d'hexaacide de formule (I) est isolé par filtration et séchage.180 kg of the hexaacid gadolinium complex of formula (I) obtained above (dry extract at approximately 72%) are suspended in 390 kg of water. The medium is heated to 100° C. to dissolve the product, then cooled to 80° C. to be primed by adding a little primer. After cooling to ambient temperature, the hexaacid gadolinium complex of formula (I) is isolated by filtration and drying.
Le produit sec est chargé dans le réacteur avec de l'eau osmosée/ à 20°C. La masse d'eau ajoutée est égale au double de la masse de complexe de gadolinium d'hexaacide de formule (I) théorique. De la soude 30,5 % (m/m) (6,5 éq) est coulée sur le milieu à 20°C. On laisse le milieu en contact à 50°C à la fin de l'ajout de NaOH pendant 16h00. Le milieu est refroidi à 25°C et le produit filtré sur un lit de Clarcel.The dry product is charged to the reactor with osmosis water at 20°C. The mass of water added is equal to twice the mass of gadolinium hexaacid complex of theoretical formula (I). 30.5% (m/m) sodium hydroxide (6.5 eq) is poured onto the medium at 20°C. The medium is left in contact at 50° C. at the end of the addition of NaOH for 16:00. The medium is cooled to 25° C. and the product filtered through a bed of Clarcel.
Le rapport dans lequel les différents isomères du complexe de formule (I) sont présents au sein du mélange de diastéréoisomères dépend des conditions dans lesquelles sont effectuées les étapes de complexation et d'isomérisation, comme cela apparaît dans le tableau 3 ci-dessous.
Les étapes additionnelles de recristallisation et décomplexation sélective permettent d'augmenter l'excès diastéréoisomérique en le mélange I-RRR et I-SSS (voir tableau 4).
Dans un réacteur, 90 kg (119 moles) du complexe d'hexaacide de formule (I) et 650 kg de méthanol sont chargés. Le mélange est refroidi à environ 0°C puis 111 kg (252 moles) d'une solution d'acide chlorhydrique méthanolique (8,25% d'HCI dans le méthanol) sont coulés en maintenant la température à 0°C. Le milieu réactionnel est porté à température ambiante puis est maintenu sous agitation pendant 16 heures. Après refroidissement à 0-5°C, 120 kg (1319 moles) d'3-amino-1,2-propanediol sont ajoutés. Le milieu réactionnel est ensuite chauffé en distillant le méthanol sous vide jusqu'à atteindre une température de 60-65°C. Le concentrât est maintenu pendant 16 heures à cette température sous vide. En fin de contact, le milieu est dilué avec 607 kg d'eau en refroidissant à température ambiante. La solution du complexe de formule (II) brut est neutralisée avec de l'acide chlorhydrique 20 % (m/m). 978,6 kg de solution sont ainsi obtenus, avec une concentration de 10,3 %, représentant 101 kg de matière. Le rendement obtenu est de 86.5 %.In a reactor, 90 kg (119 moles) of the hexaacid complex of formula (I) and 650 kg of methanol are loaded. The mixture is cooled to approximately 0°C then 111 kg (252 moles) of a solution of methanolic hydrochloric acid (8.25% HCl in methanol) are poured in while maintaining the temperature at 0°C. The reaction medium is brought to room temperature and then kept under stirring for 16 hours. After cooling to 0-5°C, 120 kg (1319 moles) of 3-amino-1,2-propanediol are added. The reaction medium is then heated by distilling the methanol under vacuum until a temperature of 60-65°C is reached. The concentrate is maintained for 16 hours at this temperature under vacuum. At the end of contact, the medium is diluted with 607 kg of water while cooling to ambient temperature. The solution of the crude complex of formula (II) is neutralized with 20% (m/m) hydrochloric acid. 978.6 kg of solution are thus obtained, with a concentration of 10.3%, representing 101 kg of material. The yield obtained is 86.5%.
Les isomères du complexe de formule (II) ont été synthétisés à partir des groupes d'isomères isoA, isoB, isoC et isoD du complexe d'hexaacide de formule (I) isolés par HPLC préparative. Les 4 groupes d'isomères ont été isolés puis amidifiés par du 3-amino-1,2-propanediol (APD) R et S. On obtient ainsi 8 isomères :
- isoA + APD(R) et isoA + APD(S),
- isoB + APD(R) et isoB + APD(S),
- isoC + APD(R) et isoC + APD(S), et
- isoD + APD(R) et isoD + APD(S).
- isoA + APD(R) and isoA + APD(S),
- isoB + APD(R) and isoB + APD(S),
- isoC + APD(R) and isoC + APD(S), and
- isoD + APD(R) and isoD + APD(S).
Chacun de ces isomères a été placé dans les conditions permettant l'isomérisation du complexe de gadolinium d'hexaacide de formule (I).Each of these isomers was placed under the conditions allowing the isomerization of the gadolinium complex of hexaacid of formula (I).
Ainsi, on prépare une solution d'HCI à pH 3 en diluant 1 mL d'HCl 1 N dans 1 litre d'eau. Les isomères sont ajoutés à une concentration de 1 mM dans la solution d'HCI à pH 3. 10 mg de poudre sont dissous dans 10 mL de cette solution. Les 8 solutions obtenues sont chauffées à 100°C puis analysées à T0 et à T0 + 23 heures par HPLC.Thus, an HCl solution at
Dans le tableau suivant, sont reportés les % de pureté mesurés par HPLC.
La perte de pureté est due à la dégradation chimique (hydrolyse des fonctions amide) du produit du fait des conditions imposées par la réaction d'isomérisation.The loss of purity is due to the chemical degradation (hydrolysis of the amide functions) of the product due to the conditions imposed by the isomerization reaction.
Comme les conditions permettant l'isomérisation des différents composés induisent une forte dégradation chimique des produits via l'hydrolyse des fonctions amide, l'isomérisation ne peut être réalisée de manière propre et sélective directement sur le complexe de formule (II) obtenu selon le procédé décrit dans le brevet
Claims (14)
- Process for preparing the complex of formula (II) below:a) Complexation of the hexaacid of formula (III) below:b) Isomerization by heating of the hexaacid gadolinium complex of formula (I) in an aqueous solution with a pH of between 2 and 4, to obtain a diastereoisomerically enriched complex consisting of at least 80% of a diastereoisomeric excess comprising a mixture of the I-RRR and I-SSS isomers of said hexaacid gadolinium complex of formula (I), of formulae:c) Formation, from the diastereoisomerically enriched complex obtained in step b), of the complex of formula (II), by reaction with 3-amino-1,2-propanediol.
- Process according to Claim 1, characterized in that the hexaacid gadolinium complex of formula (I) formed in the course of step a) is directly subjected to the isomerization step b) without being isolated or purified.
- Process according to Claim 1 or 2, characterized in that the aqueous solution of step b) comprises acetic acid.
- Process according to any one of Claims 1 to 3, characterized in that step b) is performed at a temperature of between 100°C and 120°C, typically for a time of between 12 hours and 48 hours.
- Process according to any one of Claims 1 to 4, characterized in that step b) comprises the following successive steps:b1) Isomerization by heating the hexaacid gadolinium complex of formula (I) in an aqueous solution with a pH of between 2 and 4, to obtain a diastereoisomerically enriched complex consisting of at least 80% of the diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said hexaacid gadolinium complex of formula (I), andb2) Isolation by crystallization of said diastereoisomerically enriched complex, preferably by crystallization by seeding.
- Process according to Claim 5, characterized in that the diastereoisomerically enriched complex from step b) isolated by crystallization is purified by recrystallization, to obtain a diastereoisomerically enriched and purified complex.
- Process according to Claim 5 or 6, characterized in that the diastereoisomerically enriched complex from step b) is further enriched by selective decomplexation of the diastereoisomers of the complex of formula (I) other than the I-RRR and I-SSS diastereoisomers, i.e. by selective decomplexation of the I-RSS, I-SRR, I-RSR, I-SRS, I-RRS and I-SSR diastereoisomers.
- Process according to any one of Claims 1 to 7, characterized in that the diastereoisomerically enriched complex obtained on conclusion of step b) according to any one of the variants described above has at least 85% of the diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers.
- Process according to any one of Claims 1 to 8, characterized in that the diastereoisomerically enriched complex obtained on conclusion of step b) according to any one of the variants described above has at least 90% of the diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers.
- Process according to any one of Claims 1 to 9, characterized in that step c) comprises the following successive steps:c1) formation of a triester of formula (VIII)c2) aminolysis of the triester of formula (VIII) with 3-amino-1,2-propanediol, notably in the alcohol of formula R1OH in the presence of an acid such as hydrochloric acid.
- Process according to Claim 10, characterized in that the triester of formula (VIII) is not isolated between steps c1) and c2).
- Process according to Claim 10 or 11, characterized in that R1 represents a methyl group.
- Process according to any one of Claims 1 to 12, characterized in that step c) comprises the following successive steps:c1) formation of a methyl triester of formula (IV)c2) aminolysis of the methyl triester of formula (IV) with 3-amino-1,2-propanediol in methanol in the presence of an acid such as hydrochloric acid, during which the methanol is removed by vacuum distillation, until a temperature of greater than 55°C is reached, the reaction medium being maintained at this temperature under vacuum for a time typically greater than 5 hours before being cooled to room temperature and diluted with water.
- Process according to any one of Claims 1 to 13, characterized in that the hexaacid of formula (III) as defined in Claim 1 is obtained by alkylation of pyclene of formula (V):
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21190150.9A EP3936505B1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for synthesising same |
HRP20221291TT HRP20221291T1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1900433A FR3091872B1 (en) | 2019-01-17 | 2019-01-17 | COMPLEX OF GADOLINIUM AND A LIGAND CHELATOR DERIVED FROM PCTA DIASTEREOISOMERICALLY ENRICHED AND PROCESS FOR SYNTHESIS |
PCT/EP2020/051142 WO2020148431A1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21190150.9A Division-Into EP3936505B1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for synthesising same |
EP21190150.9A Division EP3936505B1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for synthesising same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3902799A1 EP3902799A1 (en) | 2021-11-03 |
EP3902799B1 true EP3902799B1 (en) | 2022-07-27 |
Family
ID=67001954
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21190150.9A Active EP3936505B1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for synthesising same |
EP20700830.1A Active EP3902799B1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21190150.9A Active EP3936505B1 (en) | 2019-01-17 | 2020-01-17 | Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for synthesising same |
Country Status (27)
Country | Link |
---|---|
US (1) | US20220098218A1 (en) |
EP (2) | EP3936505B1 (en) |
JP (2) | JP7101897B2 (en) |
KR (2) | KR102442900B1 (en) |
CN (2) | CN113646309A (en) |
AR (1) | AR117834A1 (en) |
AU (2) | AU2020208793B2 (en) |
BR (2) | BR122022025041B1 (en) |
CA (2) | CA3126337C (en) |
CL (1) | CL2021001869A1 (en) |
CO (1) | CO2021009253A2 (en) |
DK (1) | DK3902799T3 (en) |
ES (1) | ES2929699T3 (en) |
FI (1) | FI3936505T3 (en) |
FR (1) | FR3091872B1 (en) |
HR (2) | HRP20221291T1 (en) |
HU (2) | HUE060073T2 (en) |
IL (1) | IL284883A (en) |
MA (2) | MA54624A (en) |
MX (1) | MX2021008654A (en) |
PL (1) | PL3902799T3 (en) |
PT (2) | PT3902799T (en) |
RS (1) | RS65146B1 (en) |
SG (1) | SG11202107781WA (en) |
TW (1) | TWI812832B (en) |
WO (1) | WO2020148431A1 (en) |
ZA (1) | ZA202104993B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3091873B1 (en) * | 2019-01-17 | 2020-12-25 | Guerbet Sa | COMPLEX OF GADOLINIUM AND A LIGAND CHELATOR DERIVED FROM PCTA DIASTEREOISOMERICALLY ENRICHED AND PROCESS FOR PREPARATION AND PURIFICATION |
CN114031513B (en) * | 2021-11-01 | 2022-07-26 | 中国人民解放军总医院第八医学中心 | Separation of gadoxetic acid disodium isomer and application thereof as MR imaging contrast agent |
WO2024049087A1 (en) * | 2022-09-01 | 2024-03-07 | 주식회사 테라노큐어 | Novel compound and mri contrast agent comprising same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020030618A1 (en) * | 2018-08-06 | 2020-02-13 | Bracco Imaging Spa | Gadolinium bearing pcta-based contrast agents |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
DE4001655A1 (en) | 1990-01-18 | 1991-07-25 | Schering Ag | 6-RING MACROCYCLIC TETRAAZA COMPOUNDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL PRODUCTS CONTAINING THEM |
FR2793795B1 (en) * | 1999-05-21 | 2001-08-03 | Guerbet Sa | ISOMERS OF TETRAMIDS OF THE ACID GADOLINIUM COMPLEX (1,4,7,10-TETRAZACYCLODODECANE) 1,4,7,10-TETRA (2-GLUTARIC) THEIR PREPARATION PROCESS AND THEIR APPLICATION IN MEDICAL IMAGING |
FR2794744B1 (en) * | 1999-06-09 | 2001-09-21 | Guerbet Sa | METAL COMPLEXES OF BICYCLIC POLYAMINOACIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN MEDICAL IMAGING |
FR2891830B1 (en) * | 2005-10-07 | 2011-06-24 | Guerbet Sa | SHORT AMINOALCOHOL COMPOUNDS AND METAL COMPLEXES FOR MEDICAL IMAGING |
EP2786768A1 (en) * | 2013-04-04 | 2014-10-08 | Agfa Healthcare | Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide |
EP2988756B2 (en) | 2013-04-26 | 2022-05-18 | Guerbet | Contrast medium formulation and related preparation method |
FR3091873B1 (en) * | 2019-01-17 | 2020-12-25 | Guerbet Sa | COMPLEX OF GADOLINIUM AND A LIGAND CHELATOR DERIVED FROM PCTA DIASTEREOISOMERICALLY ENRICHED AND PROCESS FOR PREPARATION AND PURIFICATION |
-
2019
- 2019-01-17 FR FR1900433A patent/FR3091872B1/en active Active
-
2020
- 2020-01-17 BR BR122022025041-6A patent/BR122022025041B1/en active IP Right Grant
- 2020-01-17 BR BR112021014087-5A patent/BR112021014087B1/en active IP Right Grant
- 2020-01-17 CN CN202080009659.7A patent/CN113646309A/en active Pending
- 2020-01-17 ES ES20700830T patent/ES2929699T3/en active Active
- 2020-01-17 EP EP21190150.9A patent/EP3936505B1/en active Active
- 2020-01-17 MX MX2021008654A patent/MX2021008654A/en unknown
- 2020-01-17 CN CN202111050874.4A patent/CN113698400A/en active Pending
- 2020-01-17 EP EP20700830.1A patent/EP3902799B1/en active Active
- 2020-01-17 KR KR1020217025765A patent/KR102442900B1/en active IP Right Grant
- 2020-01-17 SG SG11202107781WA patent/SG11202107781WA/en unknown
- 2020-01-17 HU HUE20700830A patent/HUE060073T2/en unknown
- 2020-01-17 RS RS20231021A patent/RS65146B1/en unknown
- 2020-01-17 AU AU2020208793A patent/AU2020208793B2/en active Active
- 2020-01-17 AR ARP200100124A patent/AR117834A1/en unknown
- 2020-01-17 TW TW109101778A patent/TWI812832B/en active
- 2020-01-17 CA CA3126337A patent/CA3126337C/en active Active
- 2020-01-17 CA CA3186302A patent/CA3186302C/en active Active
- 2020-01-17 JP JP2021541200A patent/JP7101897B2/en active Active
- 2020-01-17 WO PCT/EP2020/051142 patent/WO2020148431A1/en active Application Filing
- 2020-01-17 MA MA054624A patent/MA54624A/en unknown
- 2020-01-17 HU HUE21190150A patent/HUE063338T2/en unknown
- 2020-01-17 US US17/423,589 patent/US20220098218A1/en active Pending
- 2020-01-17 FI FIEP21190150.9T patent/FI3936505T3/en active
- 2020-01-17 MA MA055227A patent/MA55227A/en unknown
- 2020-01-17 PT PT207008301T patent/PT3902799T/en unknown
- 2020-01-17 HR HRP20221291TT patent/HRP20221291T1/en unknown
- 2020-01-17 HR HRP20231161TT patent/HRP20231161T1/en unknown
- 2020-01-17 PT PT211901509T patent/PT3936505T/en unknown
- 2020-01-17 PL PL20700830.1T patent/PL3902799T3/en unknown
- 2020-01-17 DK DK20700830.1T patent/DK3902799T3/en active
- 2020-01-17 KR KR1020217036450A patent/KR102593187B1/en active IP Right Grant
-
2021
- 2021-07-14 CL CL2021001869A patent/CL2021001869A1/en unknown
- 2021-07-15 CO CONC2021/0009253A patent/CO2021009253A2/en unknown
- 2021-07-15 IL IL284883A patent/IL284883A/en unknown
- 2021-07-15 ZA ZA2021/04993A patent/ZA202104993B/en unknown
- 2021-10-25 JP JP2021173862A patent/JP2022009462A/en active Pending
-
2023
- 2023-01-25 AU AU2023200400A patent/AU2023200400B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020030618A1 (en) * | 2018-08-06 | 2020-02-13 | Bracco Imaging Spa | Gadolinium bearing pcta-based contrast agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3902800B1 (en) | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process | |
EP4182314A1 (en) | Method for preparing a chelating ligand derived from pcta | |
EP3902799B1 (en) | Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method | |
RU2806027C2 (en) | Diastereoisomerically enriched complex of gadolinium and chelating ligand based on pcta, method for its preparation and purification | |
US11426470B2 (en) | Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method | |
RU2810975C2 (en) | Diastereoisomerically enriched complex of gadolinium and chelating ligand based on pcta, method of its synthesis | |
US11370804B2 (en) | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process | |
BR122022026286B1 (en) | COMPOSITION COMPRISING A GADOLINIUM COMPLEX |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20221291T Country of ref document: HR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210730 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20211115 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RAV | Requested validation state of the european patent: fee paid |
Extension state: TN Effective date: 20210730 Extension state: MA Effective date: 20210730 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: BA Payment date: 20210730 |
|
INTG | Intention to grant announced |
Effective date: 20220419 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40065708 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020004220 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1507008 Country of ref document: AT Kind code of ref document: T Effective date: 20220815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3902799 Country of ref document: PT Date of ref document: 20221017 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20221011 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20221027 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20220727 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2929699 Country of ref document: ES Kind code of ref document: T3 Effective date: 20221201 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20221291 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20220402108 Country of ref document: GR Effective date: 20221212 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E060073 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20221291 Country of ref document: HR Payment date: 20230103 Year of fee payment: 4 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20230127 Year of fee payment: 4 Ref country code: MC Payment date: 20230104 Year of fee payment: 4 Ref country code: LU Payment date: 20230127 Year of fee payment: 4 Ref country code: IE Payment date: 20230127 Year of fee payment: 4 Ref country code: FR Payment date: 20230125 Year of fee payment: 4 Ref country code: FI Payment date: 20230127 Year of fee payment: 4 Ref country code: ES Payment date: 20230201 Year of fee payment: 4 Ref country code: DK Payment date: 20230127 Year of fee payment: 4 Ref country code: CZ Payment date: 20230103 Year of fee payment: 4 Ref country code: CH Payment date: 20230130 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602020004220 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230117 Year of fee payment: 4 Ref country code: SE Payment date: 20230127 Year of fee payment: 4 Ref country code: PT Payment date: 20230102 Year of fee payment: 4 Ref country code: PL Payment date: 20230104 Year of fee payment: 4 Ref country code: IT Payment date: 20230131 Year of fee payment: 4 Ref country code: HU Payment date: 20230111 Year of fee payment: 4 Ref country code: HR Payment date: 20230103 Year of fee payment: 4 Ref country code: GR Payment date: 20230127 Year of fee payment: 4 Ref country code: DE Payment date: 20230127 Year of fee payment: 4 Ref country code: BE Payment date: 20230127 Year of fee payment: 4 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220727 |
|
26N | No opposition filed |
Effective date: 20230502 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1507008 Country of ref document: AT Kind code of ref document: T Effective date: 20220727 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20221291 Country of ref document: HR Payment date: 20240103 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240126 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240129 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20240126 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240201 Year of fee payment: 5 Ref country code: IE Payment date: 20240129 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20240105 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20240111 Year of fee payment: 5 Ref country code: FI Payment date: 20240125 Year of fee payment: 5 Ref country code: DE Payment date: 20240129 Year of fee payment: 5 Ref country code: CZ Payment date: 20240105 Year of fee payment: 5 Ref country code: PT Payment date: 20240108 Year of fee payment: 5 Ref country code: CH Payment date: 20240202 Year of fee payment: 5 Ref country code: GB Payment date: 20240129 Year of fee payment: 5 Ref country code: GB Payment date: 20240129 Year of fee payment: 4 |